Neutrophil elastase inhibitors for use in the treatment of fibrosis - Patent Application 20070123333

Alberestat, a neutrophil elastase inhibitor, addresses the inadequacies of current fibrosis treatments by reducing fibrosis in chronic graft rejection and GVHD through inhibition of neutrophil elastase, improving lung function and fibrotic activity markers.

JP2024540952AInactive Publication Date: 2024-11-06MEREO BIOPHARMA 4 LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024523709
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-20
Filing Date
2022-10-20
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for chronic graft rejection and graft-versus-host disease (GVHD) associated fibrosis, such as lung transplant-associated bronchiolitis obliterans syndrome (LT-BOS) and GVHD BOS, are inadequate, with high risks of adverse events and limited efficacy, and there is a need for new therapies to prevent or treat fibrosis in these conditions.

Method used

Administering an effective amount of a neutrophil elastase inhibitor, particularly alberestat or a pharmaceutically acceptable salt and/or solvate thereof, to subjects in need to treat or prevent fibrosis, including fibrosis associated with chronic graft rejection and GVHD.

Benefits of technology

Alberestat effectively reduces fibrosis by inhibiting neutrophil elastase activity, as evidenced by decreased biomarkers of elastin and collagen turnover, leading to improved lung function and reduced fibrotic activity in patients with LT-BOS and GVHD BOS.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540952000004
    Figure 2024540952000004
  • Figure 2024540952000005
    Figure 2024540952000005
  • Figure 2024540952000006
    Figure 2024540952000006
Patent Text Reader

Abstract

The present invention relates to the treatment of fibrosis by administering a neutrophil elastase inhibitor such as alverestat. In particular, the present invention relates to the treatment of fibrosis in combination with another disease, such as bronchiolitis obliterans syndrome, optionally associated with organ rejection, e.g. graft-versus-host disease.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application No. US 63 / 262788, filed October 20, 2021, the contents of which are incorporated herein by reference.

[0002] The present invention relates to a new method for treating or preventing fibrosis, the method comprising administering a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof, to a subject in need thereof. [Background technology]

[0003] Fibrosis Fibrosis (also known as fibrous scarring) is a major cause of morbidity and / or mortality, and there is no cure. Fibrosis refers to the development of fibrous connective tissue as a repair response to trauma or injury, and also the deposition of excess fibrous connective tissue that occurs as a pathological process. Fibrous connective tissue includes collagen fibers. Fibrosis can occur in many tissues in the body and can result from inflammation, trauma, and / or tissue (e.g., organ) transplantation. Example tissues include the lung, liver, brain, heart, gastrointestinal tract, and skin.

[0004] There is a link between the synthesis of collagen, a major component of the extracellular matrix (ECM), and fibrosis. [1] In particular, in the ECM, a balance exists between collagen production, deposition, and remodeling. However, during fibrosis, this balance is disrupted and collagen is deposited. Increased accumulation of ECM may also contribute to the pathogenesis of fibrosis. In addition, tissues affected by inflammation are more prone to fibrosis. This is because inflammation can cause excessive accumulation of extracellular matrix (ECM) components, such as collagen proteins, resulting in fibrosis that ultimately impedes normal tissue function.

[0005] Fibrosis and graft rejection Fibrosis can be observed after organ transplantation. Transplantation of organs, bone marrow, and human stem cells has advanced human health. However, transplantation is fraught with challenges due to the immune system's ability to recognize and react to non-self tissues. This is a particular risk in allogeneic transplants, where tissues are genetically similar but not from the same donor and a human leukocyte antigen (HLA) tissue type mismatch exists.

[0006] Graft rejection after solid organ transplantation can occur when the recipient's immune system (particularly the recipient's mature αβ T cells) recognizes foreign HLA antigens expressed on the cells of the donor's organ. This occurs due to host alloreactivity to mismatched donor antigens. Acute rejection typically occurs during the first week to several months after transplantation and is the main risk factor for the development of chronic rejection. Other risk factors for chronic rejection include inflammation and / or infection. Chronic rejection typically occurs several months to several years after transplantation and is the main cause of long-term graft function loss. Clinically, chronic rejection may involve the replacement of allograft parenchyma with fibrous scar tissue (i.e., fibrosis). Thus, fibrosis associated with graft rejection is undesirable.

[0007] Fibrosis and engraftment Lung transplantation is an important treatment option for patients with progressive lung disease or irreversible pulmonary failure, with approximately 3,500 lung transplants performed worldwide each year. However, acute lung rejection affects approximately one-third of all lung transplant patients during the first year after transplantation, and the increased risk of developing chronic lung rejection (or chronic pulmonary allograft dysfunction (CLAD)) remains a major obstacle to long-term survival after lung transplantation. It is the leading cause of allograft loss and death in lung transplant recipients surviving more than three months after transplantation.

[0008] Lung transplant-associated bronchiolitis obliterans syndrome (LT-BOS) is a form of CLAD that manifests as a decline in lung function, which is often progressive. It is believed to be due to inflammation, destruction, and / or fibrosis of small airways in the lung allograft, which results in bronchiolitis obliterans (OB). The median survival time after diagnosis is 3-5 years. [2] Lung transplant-associated restrictive allograft syndrome (RAS) is another form of CLAD that can manifest as a chronic, persistent restrictive decline in lung function. [3] RAS exhibits characteristics of peripheral pulmonary fibrosis and significantly impacts the survival of lung transplant patients. Therefore, fibrosis associated with graft rejection is undesirable.

[0009] Despite its high incidence, there is currently no adequate treatment for chronic graft rejection, especially for LT-BOS. Current options for chronic graft rejection, especially in LT-BOS, include immunosuppressive therapy (often triple combinations) and new macrolides (such as azithromycin), as well as treatment of associated gastroesophageal reflux and infection. However, evidence supporting currently available treatments is limited, treatment responses are usually poor, and there is a high risk of serious adverse events, and immunosuppressive therapy greatly impairs immune reconstitution, thereby increasing the risk of infection. As a last resort, lung retransplantation may be considered, but outcomes are poor and donor organs are scarce. As a result, the ISHLT / ATS / ERS BOS Task Force concluded in 2014 that currently available treatments have not been proven to provide significant benefit in the prevention or treatment of LT-BOS [4].

[0010] Fibrosis and graft-versus-host disease As an additional complication in transplant rejection, the immune response mounted by mature donor αβ T cells contained in the graft against the allogeneic transplant recipient can lead to graft-versus-host disease (GVHD). Typically, GVHD is seen in the setting of allogeneic hematopoietic stem cell transplantation, but it can also occur in immunocompromised patients when receiving blood transfusions. Whereas acute GVHD is characterized by damage to the skin, liver, lungs and / or gastrointestinal tract, chronic GVHD can have more diverse symptoms and resemble autoimmune syndromes. The standard treatment is immunosuppressive therapy, which, as mentioned above, carries a high risk of adverse events and increases the risk of infection [5]. After stem cell transplantation, subjects may develop GVHD BOS, where BOS is an example of an obstructive pulmonary disease. Alternatively, after stem cell transplantation, subjects may develop restrictive pulmonary disease, such as GVHD-related restrictive chronic pulmonary function decline (GVHD R-CLFD). [6] Restrictive and obstructive pulmonary disease may include fibrotic aspects. Therefore, GVHD-associated fibrosis is undesirable.

[0011] Neutrophil elastase (NE) inhibitors NE inhibitors have been included in the treatment of various diseases. However, the mechanisms leading to neutrophil elastase inhibition and reduction of fibrosis (especially that associated with GVHD) are not fully understood or well established. Furthermore, it is believed that therapeutic efficacy in humans has not been demonstrated so far.

[0012] Alberestat has previously been investigated in the treatment of chronic graft rejection (particularly LT-BOS) and GVHD (see WO2021 / 053058, incorporated herein by reference), and has been shown to improve lung function. However, inhibition of NE using alberestat has not been disclosed as being useful specifically in the treatment of fibrosis associated with graft rejection or GVHD, or fibrosis associated with other diseases.

[0013] Therefore, there is a need for new therapies for treating and preventing fibrosis. In particular, there is a need for new therapies for treating and preventing fibrosis associated with a disease selected from chronic graft rejection (particularly LT-BOS) and GVHD (particularly GVHD BOS). In addition, there is a need for new therapies for treating and preventing diseases, including reducing fibrosis. Summary of the Invention

[0014] Surprisingly, inhibitors of neutrophil elastase (NE), such as alberestat, demonstrate benefit in the treatment and prevention of fibrosis, particularly fibrosis associated with GVHD BOS, particularly in human subjects.

[0015] The invention described herein is unexpected because, to the best of the inventors' knowledge, there is no proven link between fibrosis and the mechanism of NE. For example, the primary driver of fibrosis is usually believed to be the excessive accumulation and / or deposition of extracellular matrix (ECM) components such as collagen, rather than neutrophils. NE inhibitors have not previously been demonstrated to be effective in treating or preventing fibrosis associated with BOS or GVHD in subjects. Indeed, to the best of the inventors' knowledge, NE inhibition has not previously been demonstrated to treat fibrosis in human subjects in need thereof.

[0016] Thus, the present invention provides a method for treating or preventing fibrosis, the method comprising administering to a subject in need thereof an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0017] The present invention further provides a method for treating or preventing tissue-associated fibrosis, the method comprising administering to a subject in need thereof an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0018] The present invention further provides a method for treating or preventing disease-associated fibrosis, the method comprising administering to a subject in need thereof an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0019] The present invention further provides a method for treating or preventing fibrosis associated with graft rejection, the method comprising administering to a subject in need thereof an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0020] The present invention further provides a method for treating or preventing graft rejection, the method comprising administering an effective amount of a neutrophil elastase inhibitor, particularly alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof, to a subject in need thereof, wherein treating comprises reducing fibrosis in the subject.

[0021] The present invention further provides a method for treating or preventing fibrosis associated with lung transplant-associated bronchiolitis obliterans syndrome (LT-BOS), the method comprising administering to a subject in need thereof an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0022] The present invention further provides a method for treating or preventing lung transplant-associated bronchiolitis obliterans syndrome (LT-BOS), the method comprising administering an effective amount of a neutrophil elastase inhibitor, particularly alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof, to a subject in need thereof, wherein treating comprises reducing fibrosis in the subject.

[0023] The present invention further provides a method for treating or preventing fibrosis associated with lung transplant-associated restrictive allograft syndrome (LT-RAS), the method comprising administering to a subject in need thereof an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0024] The present invention further provides a method for treating or preventing lung transplant-associated restrictive allograft syndrome (LT-RAS), the method comprising administering an effective amount of a neutrophil elastase inhibitor, particularly alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof, to a subject in need thereof, wherein treating comprises reducing fibrosis in the subject.

[0025] The present invention further provides a method for treating or preventing fibrosis associated with graft-versus-host disease (GVHD), the method comprising administering to a subject in need thereof an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0026] The present invention further provides a method for treating or preventing graft-versus-host disease (GVHD), the method comprising administering an effective amount of a neutrophil elastase inhibitor, particularly alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof, to a subject in need thereof, wherein the treatment comprises reducing fibrosis in the subject.

[0027] The present invention further provides a method for treating or preventing fibrosis associated with GVHD BOS, the method comprising administering to a subject in need thereof an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0028] The present invention further provides a method for treating or preventing GVHD BOS, comprising administering an effective amount of a neutrophil elastase inhibitor, particularly alberestat or its pharmacologic acceptable salt and / or solvate, to a subject in need thereof, wherein the treatment comprises reducing fibrosis in the subject. In some embodiments, the subject has undergone hematopoietic stem cell transplantation.

[0029] The present invention further provides a method for treating or preventing fibrosis associated with GVHD R-CLFD, the method comprising administering to a subject in need thereof an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0030] The present invention further provides a method for treating or preventing GVHD R-CLFD, comprising administering an effective amount of a neutrophil elastase inhibitor, particularly alberestat or its pharmacologic acceptable salt and / or solvate, to a subject in need thereof, wherein the treatment comprises reducing fibrosis in the subject. In some embodiments, the subject has undergone hematopoietic stem cell transplantation.

[0031] In the methods of the invention described herein, the subject is preferably a human subject.

[0032] In addition, as shown in the Examples, analysis of biomarkers such as desmosine and isodesmosine (DES and IDES or DES / IDES) indicates that NE activity is elevated in GVHD BOS. This observation may facilitate the use of biomarkers to help determine NE levels and identify subjects in need of NE inhibition.

[0033] Thus, the present invention provides a method for identifying a subject in need of treatment with alverestat or a pharma- ceutically acceptable salt thereof, the method comprising determining the levels of desmosine and isodesmosine in a sample from the subject, wherein elevated levels of desmosine and isodesmosine compared to baseline or reference levels identify the subject in need of treatment.

[0034] The present invention also provides a method for determining neutrophil elastase activity, the method comprising assessing levels of desmosine and isodesmosine in a sample from a subject, where elevated levels of desmosine and isodesmosine compared to baseline or reference levels indicate elevated neutrophil elastase activity.

[0035] In particular, the present invention provides a method for identifying a subject in need of treatment with a NE inhibitor, in particular alberestat, the method comprising: - taking a sample from a subject; - measuring the levels of desmosine and isodesmosine in the sample and comparing the levels to a baseline or reference level, -wherein elevated levels of desmosine and isodesmosine compared to baseline or reference levels indicate elevated neutrophil elastase activity and indicate that the subject is in need of treatment with a NE inhibitor, particularly alberestat.

[0036] In particular, the present invention provides a method for determining neutrophil elastase activity, the method comprising: - taking a sample from a subject; - measuring the levels of desmosine and isodesmosine in the sample and comparing the levels to a baseline or reference level, -wherein elevated levels of desmosine and isodesmosine compared to baseline or reference levels indicate elevated neutrophil elastase activity.

[0037] In addition, as shown in the examples, the analysis of the ratio of two biomarkers, for example, a biomarker of collagen synthesis (e.g., PRO-C3) and a biomarker of collagen degradation (e.g., C3M), serves as an indicator of fibrotic activity in subjects suffering from GVHD BOS. This observation can facilitate the use of biomarker ratios to assess fibrotic activity.

[0038] The present invention therefore also provides a method for monitoring fibrotic activity in a patient undergoing treatment with a neutrophil elastase inhibitor, in particular alberestat, comprising the steps of: - taking a sample from a subject; - measuring the level of a biomarker of collagen synthesis (e.g., PRO-C3) in the sample, and measuring the level of a biomarker of collagen degradation (e.g., C3M) in the sample; - Assessing the ratio of a collagen synthesis biomarker (e.g., PRO-C3) level to a collagen degradation biomarker (e.g., C3M) level in a subject; - comparing the ratio to a baseline or reference ratio; -wherein a decrease in the ratio compared to a baseline or reference ratio indicates decreased fibrotic activity.

[0039] Thus, the present invention also provides a method for identifying a subject in need of treatment with a neutrophil elastase inhibitor, in particular alberestat, wherein the subject suffers from a fibrotic disease, the method comprising: - taking a sample from a subject; - measuring the level of a biomarker of collagen synthesis (e.g., PRO-C3) in the sample, and measuring the level of a biomarker of collagen degradation (e.g., C3M) in the sample; - Assessing the ratio of a collagen synthesis biomarker (e.g., PRO-C3) level to a collagen degradation biomarker (e.g., C3M) level in a subject; - comparing the ratio to a baseline or reference ratio; -wherein an increase in the ratio compared to the baseline or reference ratio indicates that the subject is in need of treatment with a neutrophil elastase inhibitor. [Brief description of the drawings]

[0040] [Figure 1] Figure 1 shows percent change from baseline (%CFB) in plasma desmosine (DES) and isodesmosine (IDES) in patients (N=7) who received escalating doses of alberestat (0-240mg) over time (weeks). On the x-axis, 0 (mg) means baseline (i.e., pre-treatment at week 0), 60mg administered at week 2, 120mg administered at week 4, 180mg administered at week 6, and 240mg administered at week 8. Boxes = mean change from baseline, and whiskers = standard deviation. [Diagram 2] Figure 1 shows the percent change from baseline (%CFB) in neutrophil elastase activity in blood samples (N=7) from patients given escalating doses of alverestat (0-240 mg) over time (wk=weeks), assessed ex vivo by measuring neutrophil elastase release in response to zymosan stimulation. [Figure 3A] Figure 1 shows PRO-C3 levels (ng / mL) over time as measured in subjects receiving alberestat treatment. ULN = upper limit of normal (i.e., upper limit of the reference range). Subjects were tested every 2 weeks. [Figure 3B] 1 shows PRO-C6 levels (ng / mL) over time as measured in alberestat-treated subjects. Subjects were examined every 2 weeks. [Figure 4] Figure 1 shows the ratio of PRO-C3:C3M in blood samples over time in subjects (n=7) undergoing alberestat treatment. Subjects were examined every 2 weeks during alberestat dose escalation. [Diagram 5]The percent change from baseline (%CFB) of PRO-C3 and DES / IDES in blood samples from each subject (n=7) over the study period is shown. Subjects were examined every 2 weeks during alverestat dose escalation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0041] The following description is provided with the understanding that the present disclosure is to be regarded as an example of the claimed subject matter and is not intended to limit the scope of the appended claims to the specific embodiments illustrated. The present disclosure provides reference to various embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the present invention. The headings used throughout this disclosure are provided for convenience and should not be construed as limiting the scope of the claims in any way. An embodiment illustrated under any heading may be combined with an embodiment illustrated under any other heading.

[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Throughout this specification and in the appended claims, the following terms are defined with the following meanings unless expressly stated otherwise:

[0043] Unless the context otherwise requires, throughout this specification and claims, the term "comprise" and variations thereof, such as "comprises" and "comprising," are to be interpreted in an open-ended and inclusive sense, i.e., "including but not limited to."

[0044] Where the plural forms are used for compounds, salts, etc., this shall be construed to mean a single compound, salt, etc.

[0045] As used herein, the term "or" is generally used in its meaning including "and / or" unless the context of use clearly indicates otherwise.

[0046] Also herein, the recitation of numerical ranges by endpoints includes all numbers subsumed within that range (eg, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

[0047] As used herein, the term "about" means the recited value ±10% of the recited value.

[0048] As used herein, "treatment" or "treating" is an approach to obtain a beneficial or desired result. For purposes of the present invention, beneficial or desired results include, but are not limited to, alleviating symptoms and / or reducing the severity of symptoms associated with a disease or condition. "Treatment" or "treating" includes one or more of: a) inhibiting a disease or condition (e.g., reducing one or more symptoms resulting from a disease or condition and / or reducing the severity of the disease or condition); b) delaying or halting the onset of one or more symptoms associated with a disease or condition (e.g., stabilizing a disease or condition, slowing the worsening or progression of a disease or condition); and c) relieving a disease or condition, e.g., causing regression of clinical symptoms, alleviating a disease state, slowing the progression of a disease, improving quality of life, and / or prolonging survival.

[0049] As used herein, "prevention" or "preventing" refers to a regimen that prevents the occurrence of a disease or disorder, so that the clinical symptoms of the disease do not develop. Thus, "prevention" refers to administering treatment to a subject (e.g., administering a therapeutic agent) before the symptoms of the disease become detectable in the subject. The subject may be an individual at risk of developing a disease or disorder, for example, an individual with one or more risk factors known to be associated with the onset or development of a disease or disorder. Thus, the term "preventing" in the present invention includes administering to a subject who is going to undergo or has recently undergone transplantation and has not yet developed the associated pathology.

[0050] As used herein, the term "therapeutically effective amount" or "effective amount" refers to an amount effective to induce a desired biological or medical response, including an amount of a compound whose administration to a subject for treating a disease is sufficient to effect such treatment for the disease. An effective amount varies depending on the particular compound and the characteristics of the subject being treated, such as age, weight, etc. An effective amount may include a range of amounts. As is understood in the art, an effective amount may be one or more doses, i.e., a single dose or repeated doses may be required to achieve a desired therapeutic endpoint. An effective amount may be considered in relation to the administration of one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desired or beneficial result can be achieved or is achieved. The suitable dose of any co-administered compound may optionally be reduced due to the combined action (e.g., additive or synergistic effects) of the compounds.

[0051] The term "solvate" is used herein to describe a molecular complex comprising a compound of the invention and one or more pharma- ceutically acceptable solvent molecules, such as ethanol or water. The term "hydrate" is used when the solvent is water, and for the avoidance of any doubt, the term "hydrate" is subsumed within the term "solvate".

[0052] The term "pharmaceutically acceptable salt" refers to a physiologically or toxicologically acceptable salt, and includes, where appropriate, pharmaceutically acceptable base addition salts and pharmaceutically acceptable acid addition salts. For example, when a compound contains a basic group, such as an amino group, pharmaceutically acceptable acid addition salts that can be formed include hydrochloride, hydrobromide, sulfate, phosphate, acetate, citrate, lactate, tartrate, mesylate, succinate, oxalate, phosphate, esylate, tosylate, benzenesulfonate, naphthalenedisulfonate, maleate, adipate, fumarate, hippurate, camphorate, xinafoate, p-acetamidobenzoate, dihydroxybenzoate, hydroxynaphthoate, succinate, ascorbate, oleate, bisulfate, etc. Hemisalts of acids and bases can also be formed, such as hemisulfate and hemicalcium salts. For a review of suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection and Use" by Stahl and Wermuth (Wiley-VCH, 2011).

[0053] "Pharmaceutically acceptable" or "physiologically acceptable" means a compound, salt, composition, dosage form, etc., that is suitable for pharmaceutical use.

[0054] The term "subject" preferably refers to a human, typically a human who has received or will receive a transplant.

[0055] All documents referenced herein are incorporated by reference in their entirety for all purposes.

[0056] Alberestad A preferred neutrophil elastase inhibitor for use in the present invention is alberestat.

[0057] Alberestat is a potent, orally bioavailable neutrophil elastase inhibitor described in WO 2005 / 026123 A1 (Example 94, page 85) and [6], the entire contents of which are incorporated herein by reference. Alberestat has the chemical name N-{[5-(methanesulfonyl)pyridin-2-yl]methyl}-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide and the following chemical structure: [ka]

[0058] Alberestat is also called AZD9668 and MPH996.

[0059] Alberestat may be used in the present invention in any pharma- ceutically acceptable form, for example, any free base form, salt form, and / or solvate form. Alberestat or its pharma-ceutically acceptable salt and / or solvate may be present in any pharma-ceutically acceptable physical form, suitably in solid form.

[0060] Certain salts of arvelestat are described in WO 2010 / 094964 A1, which is incorporated herein by reference in its entirety. Described salts of arvelestat include the tosylate, p-xylene-2-sulfonate, chloride, mesylate, esylate, 1,5-naphthalenedisulfonate, and sulfate.

[0061] Preferably, arvelestat free base or arvelestat tosylate is used in the methods of the present invention, with arvelestat tosylate being more preferred.

[0062] Alverestat may also be used in any of the methods of the invention in a pharma- ceutically acceptable prodrug form.

[0063] Neutrophil elastase inhibitors Neutrophil elastase (NE) is an enzyme that attacks and continuously destroys lung tissue. Compounds that inhibit NE have been investigated in [7] and in WO2017207430, WO2017102674, WO2016050835, WO2016050835, WO2016016368, WO2016016366, WO2016016365, WO2016016364, WO2016016363, WO2015124563, WO2016020070, WO2015091281, WO2014135414, WO2014122160, WO2015096873, WO2015096872, WO2014029832, WO2014029831, WO2014029830, WO2014009425, WO2013084199, WO2013037809, WO2011103774, WO2011110858, WO2011110859, WO 2011110852, WO2011039528, WO2010034996, WO2009061271, WO2009058076, WO2009060206, WO2007137080, WO2007137080, WO2007140117, WO200 8036379, WO2008036379, WO9962538, WO9962538, WO9962514, WO9739028, WO9616080, WO9533763, WO9533762, WO9527055, WO9311760, WO922035 7, WO9215605, WO9215605, WO03058237, WO03031574, WO03031574, WO2008030158, WO2007129963, WO2007129962, WO2006098684, WO2005026124, WO2005026123, WO2005021509, WO2005021512, WO2004043924, WO2009060158, WO2009037413, WO2009013444, WO2007129060, WO2007107706, WO 2007107706, WO2006136857, WO2006082412, WO2006082412, WO9623812, WO9521855, WO9401455, WO9324519, WO9321214, WO9321210, WO9321213,Neutrophil inhibitors are known from various publications, including WO9321209, WO9321212, WO2006070012, WO2005082863, WO2005082863, WO2005082864, WO9912933, WO9912933, WO9912931, WO9736903, WO2004020412, WO2008104752, WO2008097676, WO200809767, WO2008085608 (each of which is incorporated by reference). Each of the neutrophil inhibitors described in these publications can be used in the methods of the present invention and are referred to herein individually as disclosed for use in the methods of the present invention.

[0064] In addition to the preferred neutrophil elastase inhibitor alberestat, other exemplary neutrophil elastase inhibitors that can be used in the present invention include sivelestat, ONO-5046-Na, depelestat, Prolastin, KRP-109, DX-890, preelafin, MNEI, BAY 85-8501, POL6014, alpha1-AT, sirtinol, ONO-6818 (2-(5-amino-6-oxo-2-phenyl-1,6-dihydro-pyrimidin-1-yl)-N-[(1R,2R)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide), elastatinal, SSR 69071 (2-[[6-methoxy-4-(1-methylethyl)-1,1-dioxo-3-oxo-1,2-benzisothiazol-2(3H)-yl]methoxy]-9-[2-(1-piperidinyl)ethoxy]-4H-pyrido[1,2-a]pyrimidin-4-one), and M0398 (N-(methoxysuccinyl)-L-alanyl-L-alanyl-L-prolyl-L-valine chloromethyl ketone); and pharma- ceutically acceptable salts and / or solvates thereof.In addition to the preferred neutrophil elastase inhibitor alvelestat, other exemplary neutrophil elastase inhibitors that can be used in the present invention are sivelestat, ONO-5046-Na, depelestat, Prolastin, KRP-109, DX-890, preelafin, MNEI, BAY-85-8501 (also known as PHP-303), BAY-678, DMP-777, GW-311616, POL6014, alpha1-AT, sirtinol, ONO-6818 (2-(5-amino-6-oxo-2-phenyl-1,6-dihydro-pyrimidin-1-yl)-N-[(1R,2R)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide), elastatinal, SSR 69071 (2-[[6-methoxy-4-(1-methylethyl)-1,1-dioxo-3-oxo-1,2-benzisothiazol-2(3H)-yl]methoxy]-9-[2-(1-piperidinyl)ethoxy]-4H-pyrido[1,2-a]pyrimidin-4-one), and M0398 (N-(methoxysuccinyl)-L-alanyl-L-alanyl-L-prolyl-L-valine chloromethyl ketone); and pharma- ceutically acceptable salts and / or solvates thereof. In certain embodiments, the neutrophil elastase inhibitor used in the methods of the invention is a specific and reversible inhibitor of NE, such as ONO-6818 (also known as fleselestat). In certain embodiments, the neutrophil elastase inhibitor used in the methods of the invention is an irreversible inhibitor of NE, such as DMP-777 (CAS No.: 157341-41-8). In certain embodiments, the neutrophil elastase inhibitor used in the methods of the invention is an inhibitor of NE and PR3, such as sivelestat, BAY-678 (CAS No.: 675103-36-3), BAY-85-8501 (CAS No.: 1161921-82-9), DMP-777 (CAS No.: 157341-41-8), or GW-311616 (CAS No.: 198062-54-3).

[0065] The term neutrophil elastase inhibitor includes all pharma- ceutically acceptable forms of the compound, including all pharma- ceutically acceptable salts, solvates, isomers, and prodrug forms.

[0066] In certain embodiments, the neutrophil elastase inhibitor is a small molecule compound, ie, having a molecular weight of less than about 900 daltons.

[0067] Preferably, the neutrophil elastase inhibitor is an inhibitor of human neutrophil elastase.

[0068] While many embodiments of the present invention relate to arvelestat, it will be understood that for each and every embodiment described herein that refers to "arvelestat," the present invention also provides a corresponding embodiment that includes the use of a "neutrophil elastase inhibitor."

[0069] treatment method The present invention generally provides a method of treating or preventing fibrosis, tissue-associated fibrosis, or disease-associated fibrosis (e.g., transplant rejection, lung transplant-associated bronchiolitis obliterans syndrome (LT-BOS), graft-versus-host disease (GVHD), or GVHD-associated bronchiolitis obliterans syndrome (BOS)) in a subject in need thereof, the method comprising administering to the subject an effective amount of a neutrophil elastase inhibitor, particularly alberestat, or a pharmacologic acceptable salt and / or solvate thereof.

[0070] Thus, the present invention provides a method for treating or preventing fibrosis, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof.

[0071] The present invention further provides a method for reducing fibrosis in a subject, the method comprising administering to a subject in need thereof an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0072] In certain embodiments, the fibrosis may be arthrofibrosis, which is a form of scar tissue formation (i.e., fibrosis) that may occur in one or more of the knee, hip, ankle, ankle, shoulder (frozen shoulder, adhesive capsulitis), elbow (stiff elbow), wrist, wrist, and spinal vertebrae.

[0073] In certain embodiments, the fibrosis may be liver fibrosis. Liver fibrosis may be liver cirrhosis, which refers to scar tissue and nodules that replace liver tissue and disrupt liver function. Liver fibrosis is usually caused by alcoholism, fatty liver disease, hepatitis B, or hepatitis C. Liver fibrosis may be caused by fatty liver disease, also known as non-alcoholic fatty liver disease (NAFLD). In certain embodiments, the fibrosis may be liver fibrosis associated with non-alcoholic fatty liver disease (NAFLD). In certain embodiments, the fibrosis may be associated with non-alcoholic fatty liver disease (NAFLD). In certain embodiments, NAFLD may include one or more of non-alcoholic steatosis (e.g., simple fatty liver or steatosis), non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. In certain embodiments, the fibrosis may be liver fibrosis associated with non-alcoholic steatohepatitis (NASH). In certain embodiments, the fibrosis may be associated with non-alcoholic steatohepatitis (NASH).

[0074] In certain embodiments, fibrosis may be liver fibrosis.Liver fibrosis may be the result of liver's wound healing response to repeated injury.For example, after liver injury (e.g., caused by viral hepatitis), parenchymal cells may regenerate and replace necrotic or apoptotic cells.This process may be associated with inflammatory response and deposition of ECM.If liver injury persists, liver regeneration will eventually fail and liver cells may be replaced by large amounts of ECM, leading to fibrosis.

[0075] In certain embodiments, fibrosis may be cardiac fibrosis. Cardiac fibrosis may refer to the area of ​​the heart that is damaged due to myocardial infarction that causes fibrosis. Cardiac fibrosis is also known as myocardial fibrosis. There are two forms of myocardial fibrosis. The first is interstitial fibrosis, which may be the result of congestive heart failure, hypertension and aging. The second is replacement fibrosis, which may be the result of previous myocardial infarction. In certain embodiments, myocardial fibrosis is interstitial fibrosis or replacement fibrosis.

[0076] In certain embodiments, the fibrosis can be mediastinal fibrosis, a form of fibrosis characterized by calcific fibrosis of lymph nodes that can block respiratory and vascular systems.

[0077] In certain embodiments, the fibrosis can be retroperitoneal fibrosis, which is the fibrosis of soft tissues in the retroperitoneal space, including the aorta, kidneys, and many other structures.

[0078] In certain embodiments, the fibrosis may be bone marrow fibrosis. Bone marrow fibrosis or myelofibrosis is scarring within the bone marrow that prevents the normal production of blood cells in the bone marrow.

[0079] In certain embodiments, the fibrosis may be bridging fibrosis, a type of fibrosis seen in some types of liver injury and refers to fibrosis from the portal vein to the portal triad.

[0080] In certain embodiments, the fibrosis may be nephrogenic systemic fibrosis, which may involve fibrosis of the skin, joints, eyes, and / or internal organs.

[0081] In certain embodiments, the fibrosis may be dermal fibrosis, which is scar tissue that forms in the skin in response to injury, sometimes called keloids.

[0082] In certain embodiments, the fibrosis may be scleroderma or systemic sclerosis. Scleroderma is an autoimmune disease of connective tissue that primarily affects the skin, but can also involve other organs, such as the kidneys, heart, and / or lungs.

[0083] The present invention further provides a method for treating or preventing fibrosis in a tissue, the method comprising administering an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof. In certain embodiments, the tissue is lung tissue. In certain embodiments, the tissue is liver tissue. In certain embodiments, the tissue is brain tissue. In certain embodiments, the tissue is cardiac tissue. In certain embodiments, the tissue is gastrointestinal tissue. In certain embodiments, the tissue is skin tissue.

[0084] In certain embodiments of the method for treating or preventing fibrosis in tissue, the tissue is also associated with GVHD. Thus, the present invention further provides a method for treating or preventing fibrosis in tissue associated with GVHD, comprising administering an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof. In certain embodiments, the tissue is selected from the group consisting of liver, brain, heart, gastrointestinal tissue and skin tissue. In certain embodiments, the tissue is lung tissue. In certain embodiments, the tissue is liver tissue. In certain embodiments, the tissue is brain tissue. In certain embodiments, the tissue is heart tissue. In certain embodiments, the tissue is gastrointestinal tissue. In certain embodiments, the tissue is skin tissue.

[0085] The present invention further provides a method for treating or preventing disease-associated fibrosis, the method comprising administering to a subject in need thereof an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0086] In certain embodiments, the disease may be selected from graft rejection, graft-versus-host disease (GVHD), chronic pulmonary allograft dysfunction (CLAD), lung transplant-associated bronchiolitis obliterans syndrome (LT-BOS), bronchiolitis obliterans syndrome (BOS), GVHD-associated BOS (GVHD BOS), lung transplant-associated restrictive allograft syndrome (LT-RAS), GVHD-associated restrictive chronic pulmonary decline (GVHD R-CLFD), liver disease, heart disease, liver cirrhosis, fibrothorax, radiation-induced lung injury, glial scar, arteriosclerosis, kidney disease, Crohn's disease, Dupuytren's contracture, keloid abnormalities, Peyronie's disease and adhesive capsulitis, rheumatoid arthritis, ulcerative colitis, systemic lupus erythematosus, and hypertension. In particular, the disease may be selected from LT-BOS, GVHD BOS, and BOS. In certain embodiments, the disease may be selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatosis, non-alcoholic steatohepatitis (NASH), and cirrhosis.

[0087] Fibrothorax may be characterized by severe scarring (fibrosis) and fusion of the layers of the pleural cavity surrounding the lungs, resulting in reduced lung and thoracic movement. Glial scarring may be formation (gliosis), defined as a reactive cellular process with astrogliosis occurring after injury to the central nervous system. Arteriosclerosis may result from biological aging and / or arteriosclerosis. Dupuytren's contracture (also called Dupuytren's disease, Dupuytren's disease, Viking disease, and Celtic hand) is a condition in which one or more fingers become permanently bent in a flexed position. Restrictive chronic pulmonary function decline (R-CLFD) may be defined by a restrictive decline in lung function and may involve fibrotic changes at the alveolar unit.

[0088] The present invention further provides a method for treating or preventing fibrosis associated with graft rejection, the method comprising administering to a subject in need thereof an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0089] The present invention further provides a method for treating or preventing graft rejection, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof, wherein treating comprises reducing fibrosis in the subject.

[0090] Graft rejection is also sometimes called organ transplant rejection.

[0091] Subjects suffering from acute graft rejection (such as acute lung rejection) are at increased risk of developing chronic graft rejection (such as CLAD and especially LT-BOS). Thus, the present invention further provides a method for preventing the development of fibrosis in a subject suffering from acute graft rejection, comprising administering an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof.

[0092] The methods described herein are useful for treating or preventing fibrosis associated with chronic graft rejection. In certain embodiments, the methods are for treating fibrosis associated with chronic graft rejection. In other embodiments, the methods are for preventing fibrosis associated with chronic graft rejection.

[0093] The graft may include any solid organ, particularly those solid organs that are frequently transplanted, and thus may include one or more organs selected from the group consisting of skin, kidney, heart, liver, gastrointestinal tract, lung, and pancreas.

[0094] Chronic rejection of cardiac (i.e., heart) allografts is manifested by cardiac allograft vasculopathy (CAV). It is typically characterized by occlusion of coronary vessels. The 5-year incidence of CAV is 30-40%. Thus, the present invention provides a method for treating or preventing CAV in a subject in need thereof, the method comprising administering to the subject an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0095] Chronic rejection of kidney allografts is manifested by cardiac allograft nephropathy (CAN). CAN is the main cause of kidney function decline, accounting for about 40% of graft function loss at 10 years. Therefore, the present invention provides a method for treating or preventing CAN in a subject in need thereof, comprising administering an effective amount of alberestat or its pharmacologic acceptable salt and / or solvate to the subject.

[0096] In a preferred embodiment, the transplant comprises a lung. The transplant can be a single or double lung transplant. The transplant can be a heart-lung transplant. Thus, the present invention provides a method for treating or preventing fibrosis associated with lung transplant rejection in a subject in need thereof, comprising administering an effective amount of alberestat or its pharmacologic acceptable salt and / or solvate to the subject. This can be chronic lung transplant rejection.

[0097] Chronic rejection of lung allografts is manifested by chronic pulmonary allograft dysfunction (CLAD).

[0098] Thus, the present invention provides a method for treating or preventing fibrosis associated with CLAD, the method comprising administering an effective amount of alvelestat or a pharmaceutically acceptable salt and / or solvate thereof to a subject in need thereof.

[0099] The present invention further provides a method for treating or preventing CLAD, the method comprising administering an effective amount of alberestat or a pharmaceutically acceptable salt and / or solvate thereof to a subject in need thereof, wherein treating comprises reducing fibrosis in the subject.

[0100] The phenotype of CLAD is lung transplant-associated bronchiolitis obliterans syndrome (LT-BOS). Bronchiolitis obliterans is sometimes called obliterative bronchiolitis. Fibrosis may be associated with bronchiolitis obliterans. Typical characteristics include obstructive pulmonary function defects on expiratory CT and air trapping / mosaic attenuation.

[0101] The present invention provides a method for treating or preventing fibrosis associated with LT-BOS, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof.

[0102] The present invention further provides a method for treating or preventing LT-BOS, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof, wherein the treatment comprises reducing fibrosis in the subject.

[0103] Another phenotype of CLAD is lung transplant-associated restrictive allograft syndrome (RAS), typical features of which include peripheral pulmonary fibrosis.

[0104] The present invention provides a method for treating or preventing fibrosis associated with LT-RAS, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof.

[0105] The present invention further provides a method for treating or preventing LT-RAS, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof, wherein the treatment comprises reducing fibrosis in the subject.

[0106] The method of preventing fibrosis associated with LT-BOS and / or LT-RAS according to the present invention is particularly useful for subjects at risk for LT-BOS and / or LT-RAS. Such subjects may have one or more risk factors selected from the group consisting of primary graft dysfunction, gastroesophageal reflux, infection, airway ischemia, acute rejection, lymphocytic bronchiolitis, infection and colonization by microorganisms (e.g., Pseudomonas aeruginosa and Aspergillus fumigatus), donor and recipient genetics, particulate matter and the presence of HLA antibodies, or antibodies against self-antigens (such as K-α1 tubulin and collagen V).

[0107] The present invention provides a method for treating or preventing fibrosis associated with BOS, the method comprising administering to a subject in need thereof an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0108] The present invention further provides a method for treating or preventing BOS, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof, wherein treating comprises reducing fibrosis in the subject.

[0109] The present invention provides a method for treating or preventing fibrosis associated with GVHD, the method comprising administering to a subject in need thereof an effective amount of alverestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0110] The present invention further provides a method for treating or preventing graft-versus-host disease (GVHD), the method comprising administering an effective amount of alverestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof, wherein treating comprises reducing fibrosis in the subject.

[0111] Fibrosis associated with GVHD may appear after tissue transplantation. In some embodiments, the transplant is selected from the group consisting of skin, hematopoietic stem cells, blood, and bone marrow. In a preferred embodiment, the transplant is hematopoietic stem cells. In a particular embodiment, the transplant is hematopoietic stem cells, e.g., allogeneic hematopoietic cell transplantation.

[0112] GVHD may be acute graft-versus-host disease (aGVHD). The disease may be chronic graft-versus-host disease (cGVHD). Whereas acute GVHD is usually characterized by damage to the skin, liver, and gastrointestinal tract, chronic GVHD usually has more diverse symptoms and may resemble autoimmune syndromes, for example, with skin disorders such as eosinophilic fasciitis, scleroderma, and involvement of the salivary and lacrimal glands.

[0113] An additional embodiment provides a method for inhibiting the development of symptoms such as fibrosis of GVHD, including aGVHD and cGVHD, the method comprising administering a pharmacologic effective amount of alberestat, or a pharmacologic acceptable salt and / or solvate thereof, to a recipient of an allogeneic hematopoietic stem cell transplant.

[0114] In the above methods relating to GVHD, the GVHD may be characterized by damage to one or more selected from the group consisting of eyes, joints, fascia, genitals, lungs, liver, skin, or digestive tract (e.g., mouth, esophagus).

[0115] In particular, in the above methods relating to GVHD, the GVHD may be characterized by damage to one or more selected from the group consisting of the lung, liver, skin, or gastrointestinal tract. In particular, in the above methods relating to GVHD, the GVHD may be characterized by damage to one or more selected from the group consisting of the liver, skin, or gastrointestinal tract.

[0116] Chronic GVHD may be classified according to a variety of criteria. The 2005 and 2014 National Institutes of Health Consensus Development Projects on Criteria for Clinical Trials in Chronic GVHD standardized the terminology around the chronic GVHD classification system [8].

[0117] One classification system is the NIH severity score, which is divided into mild, moderate, or severe based on the number of organs involved and the severity.Therefore, in the method of the present invention for treating cGVHD, the subject may suffer from cGVHD that is mild, moderate, or severe according to the NIH severity score.In particular, the cGVHD may be moderate or severe, and is typically severe.Furthermore, a method for improving the severity score of cGVHD in a subject suffering from cGVHD is provided herein, the method comprising administering alberestat or its pharmacologic acceptable salt and / or solvate.

[0118] Another classification system based on patient-reported outcomes is the Lee cGVHD Symptom Scale [9]. Accordingly, provided herein is a method for improving the Lee cGVHD Symptom Scale in a cGVHD patient, the method comprising administering arvelestat or a pharmaceutically acceptable salt and / or solvate thereof. In particular, provided herein is a method for improving the pulmonary score of the Lee cGVHD Symptom Scale in a subject suffering from cGVHD affecting the lungs, the method comprising administering arvelestat or a pharmaceutically acceptable salt and / or solvate thereof.

[0119] Bronchiolitis obliterans syndrome (BOS) is a rare but devastating complication of graft-versus-host disease (GVHD), which is sometimes referred to as GVHD BOS (or GVHD-associated BOS).

[0120] The present invention also provides a method for treating or preventing fibrosis associated with GVHD BOS, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof.

[0121] The present invention also provides a method for treating or preventing GVHD BOS, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof, wherein the treatment comprises reducing fibrosis in the subject.

[0122] In a preferred embodiment, the subject has undergone a hematopoietic stem cell transplant, such as an allogeneic hematopoietic cell transplant.

[0123] In a preferred embodiment, the patient is a human subject.

[0124] Thus, the present invention provides a method for treating or preventing fibrosis associated with GVHD BOS, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a human subject in need thereof, the subject having undergone a hematopoietic cell transplant.

[0125] In the above methods related to GVHD BOS, the GVHD may be characterized by damage to one or more selected from the group consisting of eyes, joints, fascia, genitals, lungs, liver, skin, or gastrointestinal tract (e.g., mouth, esophagus). In particular, in the above methods related to GVHD BOS, the GVHD may be characterized by damage to one or more selected from the group consisting of liver, skin, or gastrointestinal tract.

[0126] In certain embodiments, the subject has neutrophilia, eg, airway neutrophilia.

[0127] Also provided is alberestat or its pharmaceutically acceptable salt for use in treating or preventing fibrosis associated with GVHD BOS.In particular, also provided is alberestat or its pharmaceutically acceptable salt for use in treating or preventing fibrosis associated with GVHD BOS in a human subject, the human subject undergoing hematopoietic cell transplantation.

[0128] Also provided is the use of alberestat or its pharmaceutically acceptable salt for the manufacture of a medicament for treating or preventing fibrosis associated with GVHD BOS.In particular, also provided is the use of alberestat or its pharmaceutically acceptable salt for the manufacture of a medicament for treating or preventing fibrosis associated with GVHD BOS in a human subject, the human subject undergoing hematopoietic cell transplantation.

[0129] Restrictive chronic pulmonary function decline (R-CLFD) is also a devastating complication of graft-versus-host disease (GVHD), and this complication is sometimes referred to as GVHD R-CLFD (or GVHD-associated R-CLFD).

[0130] The present invention also provides a method for treating or preventing fibrosis associated with GVHD R-CLFD, the method comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof.

[0131] The present invention also provides a method for treating or preventing GVHD R-CLFD, the method comprising administering an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof to a subject in need thereof, wherein treating comprises reducing fibrosis in the subject.

[0132] In a preferred embodiment, the subject has undergone a hematopoietic stem cell transplant, such as an allogeneic hematopoietic cell transplant.

[0133] In a preferred embodiment, the patient is a human subject.

[0134] In some embodiments, treating, preventing, or reducing fibrosis comprises reducing the level of one or more biomarkers. In some embodiments, the subject has elevated levels of one or more biomarkers, e.g., the subject has elevated levels of one or more biomarkers before administering a NE inhibitor. In some embodiments, the subject has elevated NE activity, e.g., the subject has elevated NE activity before administering a NE inhibitor. In some embodiments, treating, preventing, or reducing fibrosis comprises reducing the level of one or more biomarkers for 8 weeks.

[0135] During collagen turnover, different peptides are generated as by-products of both collagen synthesis and degradation. By-products of collagen synthesis include propeptides of procollagen, which are cleaved before collagen is incorporated into the extracellular matrix.

[10]

[11] This results in the release of unique fragments (e.g., neoepitopes) for each individual form of collagen that can be detected in the blood. By-products of collagen degradation result from specific metalloproteases (MMPs) cleaving collagen fibers, resulting in the appearance of different neoepitopes. Both synthetic peptides and degradation neoepitopes are released into the blood circulation and can be detected in the blood. The ratio of by-products (e.g., biomarkers) of collagen synthesis to collagen degradation is a useful indicator of collagen remodeling and therefore fibrosis. For example, a decrease in the ratio between the levels of collagen synthesis by-products and collagen degradation by-products may be associated with reduced fibrosis.

[0136] In some embodiments, the biomarker is a collagen biomarker. In some embodiments, the biomarker is a collagen synthesis biomarker. In some embodiments, the collagen synthesis biomarker is a collagen type III biomarker and / or a collagen type VI biomarker. In some embodiments, the collagen synthesis biomarker is a collagen type III biomarker and a collagen type VI biomarker. In some embodiments, the collagen type III biomarker is the N-terminal propeptide of collagen type III (PRO-C3). In some embodiments, the collagen type VI biomarker is the N-terminal propeptide of collagen type VI (PRO-C6). In some embodiments, the biomarker is PRO-C3. In some embodiments, the biomarker is PRO-C6.

[0137] In healthy volunteers, plasma PRO-C3 levels (i.e., reference levels) were about 10 + / - 2 ng / ml as measured by competitive ELISA.[1] In some embodiments, the reference level of PRO-C3 is about 8-12, about 9-11, or about 10 ng / ml. In some embodiments, the reference level is measured by competitive ELISA.

[0138] In healthy volunteers, plasma PRO-C6 levels (i.e., reference levels) were about 8 + / - 1 ng / ml as measured by competitive ELISA.[1] In some embodiments, the reference level of PRO-C3 is about 7-9, or about 8 ng / ml. In some embodiments, the reference level is measured by competitive ELISA.

[0139] In some embodiments, treating, preventing, or reducing fibrosis comprises reducing the levels of PRO-C3 and / or PRO-C6.

[0140] In some embodiments, the biomarker is a collagen degradation biomarker. In some embodiments, the collagen degradation biomarker is a collagen type III biomarker (C3M) and / or a collagen type VI biomarker (C6M). In some embodiments, the collagen biomarker is a collagen type III biomarker (C3M) and a collagen type VI biomarker (C6M). In some embodiments, the biomarker is C3M. In some embodiments, the biomarker is C6M.

[0141] In some embodiments, the biomarker is an elastin biomarker. In some embodiments, the elastin biomarker is selected from desmosine (DES) and isodesmosine (IDES). In some embodiments, the elastin biomarker is desmosine (DES). In some embodiments, the elastin biomarker is isodesmosine (IDES).

[0142] In healthy volunteers, the plasma DES / IDES level (i.e., the reference level) was about 0.2 ng / ml using LC-MS / MS. The plasma DES / IDES level refers to the total concentration of DES and IDES. Thus, in some embodiments, the levels of desmosine (DES) and isodesmosine (IDES) are the total levels of desmosine (DES) and isodesmosine (IDES). In some embodiments, the reference level of desmosine (DES) and isodesmosine (IDES) is 0.2 ng / ml. In some embodiments, the reference level is measured by LC-MS / MS.

[0143] Thus, in some embodiments, treating, preventing, or reducing fibrosis involves lowering the levels of desmosine (DES) and isodesmosine (IDES).

[0144] Thus, in some embodiments, treating, preventing, or reducing fibrosis comprises reducing the levels of desmosine (DES), isodesmosine (IDES), PRO-C3 and PRO-C6.

[0145] Thus, in some embodiments, treating, preventing, or reducing fibrosis comprises reducing the levels of desmosine (DES), isodesmosine (IDES), and PRO-C3.

[0146] Thus, in some embodiments, treating, preventing, or reducing fibrosis comprises decreasing the ratio of PRO-C3:C3M, hi some embodiments, treating, preventing, or reducing fibrosis comprises decreasing the ratio of PRO-C6:C6M.

[0147] A decrease in the level of any of the biomarkers described herein (e.g., one or more of PRO-C3, PRO-C6, DES and IDES, C3M and C6M) can be determined by a method (e.g., an ex vivo method). For example, the level of a biomarker can be determined by taking a blood sample from a subject and evaluating the sample by an ex vivo method. A decrease in the level of a biomarker can be determined by establishing a baseline or reference level of the biomarker before administering a NE inhibitor described herein, and then determining the level of the biomarker after administering a NE inhibitor described herein.

[0148] In the described method, the NE inhibitor, particularly arvelestat or its pharmaceutically acceptable salt and / or solvate, can be administered to the subject prior to transplantation. For example, administration of arvelestat can be started 14 days, 7 days, 3 days, 2 days, or 1 day prior to transplantation.

[0149] In the described method, the NE inhibitor, particularly arvelestat or its pharmaceutically acceptable salt and / or solvate, can be administered to the subject after transplantation.For example, administration of arvelestat can be started on the day of transplantation or 1 day, 2 days, 3 days, 7 days or 14 days after transplantation.

[0150] The method according to the invention for BOS, particularly LT-BOS or GVHD BOS, may also include improving one or more lung function parameters in a subject.The method according to the invention for restrictive lung disease, particularly LT-RAS, R-CLFD or GVHD R-CLFD, may also include improving one or more lung function parameters in a subject.

[0151] In particular, the methods of the present invention can improve a subject's FEV1. Forced expiratory volume (FEV) is the maximum forced expiratory volume measured over a set period of time, for example, 1 second (FEV1).

[0152] In particular, the methods of the present invention can improve a subject's predicted FEV1%, which is the ratio of the subject's FEV1 to the predicted FEV1 of a standard human of a similar matched race or ethnicity, sex, age, height and weight, expressed as a percentage.

[0153] Thus, there is also provided a method for increasing predicted FEV1% in a subject suffering from fibrosis and LT-BOS by administering an effective amount of a NE inhibitor, particularly alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0154] Thus, there is also provided a method for increasing predicted FEV1% in a subject suffering from fibrosis and GVHD BOS by administering an effective amount of a NE inhibitor, particularly alberestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0155] In certain embodiments, treatment with an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof increases predicted FEV1% by at least about 1%, 1.5%, 2.0%, 2.5%, 3.0%, 4.0%, 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, 10%, 15%, 20%, 30%, 40% or 50% as compared to baseline FVC% predicted measurement. In further embodiments, treatment with an effective amount of alberestat or a pharma-ceutically acceptable salt and / or solvate thereof prevents a decline in FEV1%.

[0156] The method according to the invention for LT-BOS or GVHD BOS may also include improving the subject's BOS grade. The BOS classification scheme adopted in 1993 provides a staging system based on the severity of post-transplant lung function decline and is used for clinical decision-making and research purposes. This staging system was most recently modified in 2002 [2]. The BOS classification scheme from 2002 is used according to the invention. [Table 1]

[0157] Thus, in embodiments relating to the treatment of fibrosis associated with LT-BOS or GVHD BOS, treatment with an effective amount of alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof, improves the BOS grade by at least 1 grade. In further embodiments relating to the treatment of fibrosis associated with LT-BOS or GVHD BOS, treatment with an effective amount of alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof, prevents a decrease in the BOS grade.

[0158] The diagnosis of BOS can be made by a skilled clinician. Imaging studies such as high-resolution chest CT scans and pulmonary function tests can assist in detecting BOS. Chest x-rays may also be used. Surgical lung biopsies may be performed to diagnose BOS. Lung biopsies may reveal involvement of small airways with fibrotic obstruction of the lumen. Bronchoalveolar lavage (BAL) may reveal neutrophilic and / or lymphocytic inflammation.

[0159] Also provided herein is a method for treating or preventing fibrosis associated with BOS and connective tissue diseases, systemic lupus erythematosus, rheumatoid arthritis, infection, toxic odor exposure, or Stevens-Johnson syndrome, the method comprising administering to a subject in need thereof an effective amount of a neutrophil elastase inhibitor, particularly alberestat, or a pharma- ceutical acceptable salt and / or solvate thereof.

[0160] A patient treated with the methods of the invention, in some embodiments, can have a baseline FEV1 of 30% or more of predicted FEV1, e.g., a baseline FEV1 of 35% or more, or 40% or more. A patient can have a baseline FEV1 of 20-90% of predicted FEV1, e.g., 30-80%, 35-75%, or 40-50%.

[0161] Without wishing to be bound by theory, it is believed that arbelestat is useful in the method of the present invention due to its ability to inhibit neutrophil elastase.Therefore, the present invention also provides a method for inhibiting neutrophil elastase in a subject suffering from or at risk of any of the pathologies described herein, including fibrosis associated with graft rejection, fibrosis associated with GVHD, fibrosis associated with LT-BOS, fibrosis associated with BOS, or fibrosis associated with GVHD BOS, comprising administering to the subject an effective amount of a neutrophil elastase inhibitor, particularly arbelestat or its pharmacologic acceptable salt and / or solvate.

[0162] Thus, the present invention provides a method for inhibiting neutrophil elastase in a subject suffering from or at risk of fibrosis associated with LT-BOS, BOS, or GVHD BOS, the method comprising administering to the subject an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0163] In particular, the present invention also provides a method for inhibiting neutrophil elastase in a subject suffering from or at risk of fibrosis associated with GVHD BOS, the method comprising administering to the subject an effective amount of a neutrophil elastase inhibitor, in particular alberestat or a pharma- ceutically acceptable salt and / or solvate thereof, wherein the subject has undergone a hematopoietic cell transplant.

[0164] Also provided is each of the above methods of treating or preventing any of the conditions described herein by inhibiting neutrophil elastase, the method comprising administering to a subject an effective amount of a neutrophil elastase inhibitor, particularly alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0165] The present invention also relates to a method for improving pulmonary function in a subject referred to in this disclosure, particularly a subject suffering from fibrosis associated with GVHD affecting the lung, comprising administering to the subject an effective amount of a NE inhibitor, particularly alberestat or a pharma- ceutically acceptable salt and / or solvate thereof. In some embodiments, the GVHD is chronic GVHD.

[0166] The present invention also relates to a method for preventing the deterioration of pulmonary function in a subject referred to in this disclosure, particularly a subject suffering from fibrosis associated with GVHD affecting the lung, comprising administering to the subject an effective amount of a NE inhibitor, particularly alberestat or a pharma- ceutically acceptable salt and / or solvate thereof. In some embodiments, the GVHD is chronic GVHD.

[0167] The present invention also relates to a method for stabilizing the pulmonary function of a subject referred to in this disclosure, particularly a patient suffering from fibrosis associated with GVHD affecting the lung, comprising administering to the subject an effective amount of a NE inhibitor, particularly alberestat or a pharma- ceutically acceptable salt and / or solvate thereof. In some embodiments, the GVHD is chronic GVHD.

[0168] The present invention also relates to a method for preventing the progression or worsening of fibrosis in a subject referred to in this disclosure, particularly a subject suffering from GVHD, such as cGVHD. The present invention also relates to a method for stabilizing fibrosis in a subject referred to in this disclosure, particularly a subject suffering from GVHD, such as cGVHD. In some embodiments, the GVHD is chronic GVHD.

[0169] The present invention also relates to a method for preventing the progression of fibrosis in a subject referred to in this disclosure, particularly a subject suffering from GVHD, such as cGVHD.The present invention also relates to a method for stabilizing fibrosis in a subject referred to in this disclosure, particularly a subject suffering from GVHD, such as cGVHD.

[0170] Also provided is alberestat or its pharmaceutically acceptable salt and / or solvate for use in the treatment or prevention of fibrosis associated with transplant rejection.In some embodiments, the transplant rejection is chronic or acute transplant rejection.Alberestat or its pharmaceutically acceptable salt for use in the treatment or prevention of fibrosis associated with lung transplant-associated bronchiolitis obliterans syndrome is also provided.Alberestat or its pharmaceutically acceptable salt for use in the treatment or prevention of fibrosis associated with GVHD is also provided.

[0171] Also provided is the use of alberestat or its pharmaceutically acceptable salt and / or solvate for the manufacture of a medicament for treating or preventing fibrosis associated with transplant rejection.In some embodiments, the transplant rejection is chronic.Also provided is the use of alberestat or its pharmaceutically acceptable salt for the manufacture of a medicament for treating or preventing fibrosis associated with lung transplant-associated bronchiolitis obliterans syndrome.Also provided is the use of alberestat or its pharmaceutically acceptable salt for the manufacture of a medicament for treating or preventing fibrosis associated with GVHD.

[0172] Generally, any method of treating or preventing a disease described herein comprising administering an effective amount of a product to a subject in need thereof provides a corresponding embodiment for the product for use in the method of treating or preventing a disease described herein. Additionally, embodiments are provided for the use of the product in the manufacture of a medicament for treating or preventing a disease described herein.

[0173] method As discussed above, the present invention indicates that a subject with elevated levels of a biomarker has elevated levels of activity, eg, NE activity.

[0174] Thus, the present invention provides a method for identifying a subject in need of treatment with alverestat or a pharma- ceutically acceptable salt thereof, the method comprising determining the levels of desmosine and isodesmosine in a sample from the subject, wherein elevated levels of desmosine and isodesmosine compared to baseline or reference levels identify the subject in need of treatment.

[0175] Elevated levels of desmosine and isodesmosine compared to baseline or reference levels equates to elevated neutrophil elastase activity. The levels of desmosine and isodesmosine can be determined by taking a sample (e.g., a blood sample from a subject) and determining the level of the biomarker by a method (e.g., an ex vivo method).

[0176] Thus, the present invention further provides a method of determining neutrophil elastase activity, the method comprising assessing the levels of desmosine and isodesmosine in a sample from a subject, wherein elevated levels of desmosine and isodesmosine compared to baseline or reference levels indicate elevated neutrophil elastase activity.

[0177] The present invention also provides a method for identifying a subject in need of treatment with alverestat or a pharma- ceutically acceptable salt thereof, the method comprising determining the levels of PRO-C3 and / or PRO-C6 in a sample from the subject, wherein elevated levels of PRO-C3 and / or PRO-C6 compared to baseline or reference levels identify the subject in need of treatment.

[0178] The invention also provides a method for monitoring fibrotic activity in a patient undergoing treatment with a neutrophil elastase inhibitor, in particular alberestat, comprising the steps of: - taking a sample from a subject; - measuring the level of a biomarker of collagen synthesis (e.g., PRO-C3) in the sample, and measuring the level of a biomarker of collagen degradation (e.g., C3M) in the sample; - Assessing the ratio of a collagen synthesis biomarker (e.g., PRO-C3) level to a collagen degradation biomarker (e.g., C3M) level in a subject; - comparing the ratio to a baseline or reference ratio; -wherein a decrease in the ratio compared to a baseline or reference ratio indicates decreased fibrotic activity.

[0179] The invention also provides a method for identifying a subject in need of treatment with a neutrophil elastase inhibitor, particularly alberestat, wherein the subject suffers from a fibrotic disease, the method comprising: - taking a sample from a subject; - measuring the level of a biomarker of collagen synthesis (e.g., PRO-C3) in the sample, and measuring the level of a biomarker of collagen degradation (e.g., C3M) in the sample; - Assessing the ratio of a collagen synthesis biomarker (e.g., PRO-C3) level to a collagen degradation biomarker (e.g., C3M) level in a subject; - comparing the ratio to a baseline or reference ratio; -wherein an increase in the ratio compared to the baseline or reference ratio indicates that the subject is in need of treatment with a neutrophil elastase inhibitor.

[0180] In some embodiments, the subject has been diagnosed with BOS. In some embodiments, the BOS is GVHD BOS. In some embodiments, the subject has undergone a hematopoietic stem cell transplant.

[0181] In some embodiments, the levels of PRO-C3, PRO-C6, C3M, and / or C6M are measured by chromatography and / or mass spectrometry, for example, isotope dilution liquid chromatography tandem with mass spectrometry. In some embodiments, the sample from the subject is a plasma sample.

[0182] dosage With regard to the above-mentioned treatment guidelines, the dose of the neutrophil inhibitor, particularly alberestat or its pharma- ceutically acceptable salts and / or solvates, administered depends on the disease to be treated, the severity of the disease, the mode of administration, the age, weight, and sex of the patient. Such factors may be determined by the attending physician. In general, however, satisfactory results are obtained when the compound is administered to humans at a daily dosage of 0.1 mg / kg to 100 mg / kg (measured as active ingredient).

[0183] Suitably, the daily dose is 0.5-1000 mg per day, for example 50-800 mg per day, particularly 50-600 mg per day, more particularly 120 mg-550 mg per day, even more particularly 200-500 mg per day. For example, the daily dose is about 240, 270, 300, 330, 360, 390, 420, 450 or 480 mg per day. The dose may be administered as a single dose or divided doses, for example, the total daily dose is divided into two or more fractions and administered during the day. The dose may be administered once a day, or multiple times a day (for example, twice a day), or multiple times a week, or once a month, or multiple times a month.

[0184] In a particular embodiment, arvelestat or its pharmaceutically acceptable salt and / or solvate is administered twice a day (BID administration).In a further embodiment, arvelestat or its pharmaceutically acceptable salt and / or solvate is administered twice a day, where each dose is equal to up to 240mg of arvelestat free base, for example, 60mg twice a day, 90mg twice a day, 120mg twice a day, 150mg twice a day, 180mg twice a day, 210mg twice a day, or 240mg twice a day.In particular, 120mg is administered twice a day, or 240mg is administered twice a day.

[0185] The compound may be administered to the individual according to an effective dosing regimen for a desired period or duration, e.g., at least one week, at least about one month, at least about two months, at least about three months, at least about six months, at least about twelve months, at least about twenty-four months, or more. For example, the compound may be administered on a daily or intermittent schedule for the duration of the subject's life.

[0186] The dose of alberestat or its pharmaceutically acceptable salts and / or solvates may be administered according to a dosage escalation regimen in all methods of the present invention. This allows for safe titration up to a standard daily dose of alberestat, e.g., 240 mg twice daily. For example, a standard dosage escalation regimen of alberestat to 240 mg twice daily according to the present invention includes administering alberestat or its pharmaceutically acceptable salts and / or solvates at a dose of 60 mg twice daily in a first period, followed by 120 mg twice daily in a second period, followed by 180 mg twice daily in a third period, followed by 240 mg twice daily. The first, second, and third periods may each be 10 to 20 days, e.g., each about 2 weeks. In particular, arvelestat or a pharma- ceutically acceptable salt and / or solvate thereof is administered at 60 mg twice daily for two weeks, followed by 120 mg twice daily for two weeks, followed by 180 mg twice daily for two weeks, then 240 mg twice daily. The doses are referred to as the equivalent of arvelestat free base.

[0187] composition The neutrophil inhibitor, in particular alberestat or a pharma- ceutically acceptable salt and / or solvate thereof, is administered to the subject in the form of a pharmaceutical composition.

[0188] Thus, the present invention provides a method for treating or preventing any of the conditions described herein, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a neutrophil elastase inhibitor, in particular alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof, and one or more pharma- ceutically acceptable excipients.

[0189] Pharmaceutical compositions may be prepared with one or more pharma- ceutically acceptable excipients, which can be selected in accordance with routine practice.

[0190] "Pharmaceutically acceptable excipients" include, but are not limited to, any adjuvant, carrier, filler, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier approved by the United States Food and Drug Administration as acceptable for human use. All compositions may optionally contain any of the following: th edition, 2017. Excipients may include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid, and the like.

[0191] Pharmaceutical compositions include those suitable for various administrations, including oral administration. The compositions may be provided in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of combining the active ingredient (e.g., a compound of the present disclosure or a pharmaceutical salt thereof) with one or more pharma- ceutically acceptable excipients. The compositions may be prepared by uniformly and intimately combining the active ingredient with liquid excipients or finely divided solid excipients or both, and then, if necessary, shaping the product. Techniques and formulations are generally described in Remington: The Science and Practice of Pharmacy, 22 nd It is described in the 2012 Edition.

[0192] Preferred pharmaceutical compositions are solid dosage forms, including solid oral dosage forms such as tablets. Tablets may contain excipients including glidants, fillers, binders, and the like.

[0193] In carrying out the methods described herein, the pharmaceutical composition can be administered in any form and route that makes the compound bioavailable.Thus, the pharmaceutical composition can be administered by various routes, including oral and parenteral routes, more specifically, by inhalation, subcutaneous, intramuscular, intravenous, transdermal, intranasal, rectal, intravaginal, ocular, topical, sublingual, and buccal, intraperitoneal, intravenous, intraarterial, transdermal, sublingual, intramuscular, rectal, oral, intranasal, intraadipose, intrathecal, as well as via local delivery, for example, by catheter or stent.Preferably, the pharmaceutical composition is administered orally.

[0194] When used for oral use, tablets, troches, lozenges, aqueous solutions or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. The compositions described herein suitable for oral administration may be provided as individual units (unit dosage forms), including but not limited to capsules, cachets, or tablets, each containing a predetermined amount of active ingredient. Preferably, the pharmaceutical composition is a tablet.

[0195] Aqueous compositions may be prepared in sterile form and, if intended for delivery by other than oral administration, will generally be isotonic.

[0196] The amount of active ingredient that can be combined with the inactive ingredients to produce a dosage form can vary depending on the intended therapeutic subject and the particular mode of administration.

[0197] Combination therapy In the present invention, the method may further include administering one or more additional therapeutic agents to the subject. The administration of the one or more additional therapeutic agents may be performed before, simultaneously with, or after the administration of the neutrophil inhibitor.

[0198] Additional therapeutic agents include immunosuppressants, anti-infective agents, anti-inflammatory agents, anti-fibrotic agents, and analgesics.

[0199] In certain embodiments, the one or more additional therapeutic agents are immunosuppressants, for example, one, two, or preferably three immunosuppressants may be administered.

[0200] Immunosuppressants include, for example, corticosteroids (e.g., methylprednisolone, prednisone, budesonide, dexamethasone), Janus kinase inhibitors (e.g., tofacitinib), calcineurin inhibitors (e.g., cyclosporine, tacrolimus), mTOR inhibitors (e.g., sirolimus, everolimus, temsirolimus), biologics (e.g., abatacept, adalimumab, anakinra, cel The therapeutic agent may be selected from the group consisting of: trizomab, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, secukinumab, tocilizumab, ustekinumab, vedolizumab), monoclonal antibodies (e.g., basiliximab, daclizumab), tyrosine kinase inhibitors (e.g., imatinib), thalidomide, pentostatin, azathioprine, mycophenolate and methotrexate.

[0201] In certain embodiments, the method further comprises administering to the subject a triple immunosuppressant combination, for example, tacrolimus, mycophenolate, and a corticosteroid.

[0202] The one or more additional therapeutic agents may be an anti-infective agent, including antibiotics, antifungals, anthelmintics, antimalarials, antiprotozoal agents, antituberculous agents, and antivirals.

[0203] The one or more additional therapeutic agents may be anti-infective agents. Anti-inflammatory agents include steroids such as glucocorticoids. Anti-inflammatory agents may be selected from hydrocortisone, cortisone, prednisone, prednisolone, methylprednisone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone, and beclomethasone.

[0204] The one or more additional therapeutic agents may be an anti-fibrotic agent. The anti-fibrotic agent may be selected from nintedanib and pirfenidone.

[0205] The one or more additional therapeutic agents may be budesonide, beclomethasone dipropionate, cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, tyromisole, imuthiol, antithymocyte globulin, azathioprine, azodiacarbonide, bisindolylmaleimide VIII, brequinar, chlorambucil, CTLA4-Ig, cyclophosphamide, deoxyspergualin, leflunomide, mercaptopurine, 6-mercaptopurine, methotrexate, mizoribine, mizoribine monophosphate, muromonab-CD3 ... cil, OKT3, rho(D) immunoglobulin, vitamin D analogs, MC1288), daclizumab, infliximab, rituximab, tocilizumab, alemtuzumab, methotrexate, antithymocyte globulin, denileukin diftitox, Campath-1H, keratinocyte growth factor, abatacept, remestemcel L suberoylanilide hydroxamic acid, pentostatin, thalidomide, imatinib mesylate, cyclophosphamide, fludarabine, OKT3, melphalan, thiopetagravir, and lymphocyte immunoglobulin, antithymocyte, and globulin.

[0206] It should further be understood that each of the agents administered individually or in combination in a combination therapy or regimen may be administered at an initial dose and then tapered over time by a medical professional until a lower effective dose is reached. For example, in the combinations and regimens herein, systemic glucocorticosteroids (corticosteroids), such as prednisone and methylprednisone, may be administered to a human patient at a dose of about 1-2 mg / kg / day. Initial daily doses of mTOR agents include sirolimus at 2-40 mg once daily and everolimus at 0.25-1 mg twice daily. Initial daily doses of calcineurin agents include tacrolimus at about 0.025-0.2 mg / kg / day and cyclosporine at about 2.5-9 mg / kg / day. Mycophenolate mofetil (CellCept®) may be administered at an initial daily dose of about 250-3,000 mg / day. Each of these agents may be administered following hematopoietic cell transplantation in combination with a pharma- tically effective amount of a Syk inhibitor as described herein. In different embodiments herein, agents useful for treating GVHD may be administered locally to a person in need of such treatment, for example, in the form of a topical ointment or cream, or in an eye drop formulation.

[0207] The present invention also provides a method for treating GVHD, the method further comprising the step of administering phototherapy (also known as extracorporeal photopheresis). EXAMPLES

[0208] The embodiments provided herein can be more fully understood by referring to the following examples. These embodiments are meant to illustrate the methods described herein, and are not intended to be limiting in any way. It will be apparent to those skilled in the art that various changes and modifications can be made. Such modifications are also intended to be included within the scope of the appended claims.

[0209] The alberestat used in the following examples can be synthesised according to WO 2005 / 026123 A1 (Example 94, page 85).

[0210] Alberestat according to WO2021 / 053058 (herein incorporated by reference, see in particular Examples 1-5) -A potent and specific inhibitor of neutrophil elastase (NE), -Protective effect against GVHD -It can be used as a preventive measure against the development of BOS in patients after lung transplantation, -It can be used to treat BOS in patients after lung transplantation, -To be evaluated in a Phase 1 study of alverestat in patients with bronchiolitis obliterans syndrome (BOS) following hematopoietic cell transplantation (HCT).

[0211] Example 1: Phase 1b study of alverestat, an oral neutrophil elastase inhibitor, in patients with bronchiolitis obliterans syndrome after hematopoietic cell transplantation: Effects on elevated elastase and collagen turnover biomarkers

[0212] preface Bronchiolitis obliterans syndrome (BOS) is a rare but devastating complication of chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and is associated with high morbidity and mortality. Treatment options for BOS are scarce, and new strategies are needed. Airway neutrophilia is a hallmark of BOS, even in the absence of infection, and neutrophil elastase (NE) is an enzyme implicated in the pathogenesis of BOS. A phase 1b trial of alverestat, an oral NE inhibitor, in patients with BOS after HCT is underway. Biomarkers including the elastinolytic peptides desmosine (DES) and isodesmosine (IDES), as well as stimulated neutrophil elastase, were used to assess the direct effect on NE activity. Neoepitope by-products of collagen types 3 and 6 synthesis (PRO-C3 and PRO-C6) are measured as biomarkers of fibrosis / tissue modeling. Neoepitope by-products of collagen types 3 and 6 degradation (C3M and C6M) can also be measured as biomarkers of fibrosis / tissue modeling.

[0213] method Patients with BOS and chronic GVHD, age ≥18 years, post-HCT, were recruited into a National Cancer Institute protocol (NCT02669251). This phase 1 study had two parts: an 8-week intrapatient dose escalation period, followed by a continuation period during which treatment was allowed for up to 6 months. Alberestat was administered orally, starting at 60 mg twice daily and increasing every 2 weeks to 120 mg twice daily, 180 mg twice daily, and finally 240 mg twice daily.

[0214] Blood biomarkers of neutrophil elastase activity, desmosine, isodesmosine, PRO-C3, and PRO-C6 were collected at baseline (before treatment with alberestat) and every 2 weeks during alberestat dose escalation, i.e., after 60 mg twice daily, 120 mg twice daily, 180 mg twice daily, and 240 mg twice daily.

[0215] Plasma DES and IDES levels were measured by isotope dilution liquid chromatography / mass spectrometry (Huang et al Thorax 2012;67:502-508).

[12]

[13]

[0216] Biomarkers of novel epitopes (neoepitopes) associated with collagen turnover and fibrosis (PRO-C6, PRO-C3, C3M, and C6M) were measured by competitive enzyme-linked immunosorbent assay (ELISA) (Nordic Biosciences, Denmark) [1].

[0217] Ex-vivo zymosan-stimulated neutrophil elastase (NE) activity was measured by the following assay: zymosan was added to whole blood to induce degranulation of leukocytes, including neutrophils, releasing excess free active NE into the plasma. Blood was centrifuged and the plasma removed. Levels of NE in plasma samples were measured by ProteaseTag® active neutrophil elastase immunoassay (ProAxsis Ltd, Belfast, Northern Ireland).

[0218] Results were expressed as the mean and standard error of the mean (SEM). Samples were taken at baseline and at the end of each dose escalation phase.

[0219] result Seven patients were enrolled (3 men and 4 women). At enrollment, the median post-bronchodilator FEV1 was 44% predicted (range 38-74). All seven patients were able to tolerate dose escalation of alverestat to a maximum dose of 240 mg twice daily.

[0220] DES and IDES were elevated at baseline (mean 0.464 (SEM 0.0508) ng / ml, 6 of 7 subjects were above the upper limit of normal (ULN, 0.280 ng / ml)). Levels progressively declined during the dose escalation period to 0.380 (SEM 0.0419) ng / ml by week 8, representing a mean subject % change from baseline of -16.2% (SEM 6.794, Figure 1).

[0221] Ex vivo zymosan-stimulated elastase activity also showed a gradual decline over the dose-escalation period, with some subjects showing 100% inhibition (Figure 2).

[0222] Collagen synthesis, measured by PRO-C3 and PRO-C6, was elevated above the ULN at baseline and was reduced by alberestat treatment (Figures 3A and 3B).

[0223] Consistent inhibitory effects on biomarkers of elastase activity and collagen turnover were seen in six of seven treated patients, all of whom experienced improvement or stabilization of their lung disease (defined as a <10% decrease in predicted FEV1% at the end of treatment from baseline levels).

[0224] An indication of a decrease in fibrotic activity can be observed in FIG. 4, which shows a decrease in the ratio between PRO-C3 (collagen synthesis biomarker) and C3M (collagen synthesis biomarker) during the study.

[0225] These results also support a mechanistic link between the inhibition of elastase by alberestat and the antifibrotic effect. Figure 5 shows the percent change from baseline (%CFB) of DES / IDES (elastin biomarker) relative to PRO-C3 (collagen synthesis biomarker) in subjects. As can be seen in Figure 5, there is a positive correlation indicating a mechanistic link.

[0226] conclusion This is the first evidence of elevated elastase activity as detected by elastin degradation in cGVHD BOS patients.

[0227] Treatment with the selective NE inhibitor alverestat was associated with a gradual decrease in plasma desmosine and idesmosine levels and a decrease in stimulated neutrophil elastase activity with escalating doses over 8 weeks.Treatment with the selective NE inhibitor alverestat was associated with a gradual decrease in plasma PRO-C3 with escalating doses over 8 weeks.

[0228] Thus, inhibition of NE suppresses elastase activity, since the levels of elastin degradation biomarkers are reduced. Inhibition of NE also inhibits fibrosis, since the levels of biomarkers related to collagen synthesis are reduced. Furthermore, this data also supports a mechanistic link between NE inhibition by alberestat and reduced fibrosis given the coordinated inhibition of elastin and collagen synthesis biomarkers. A way to observe reduced fibrosis may be by the ratio of the levels of collagen synthesis biomarkers to the levels of collagen degradation biomarkers (representing fibrotic remodeling), e.g., the ratio of each relevant biomarker, such as PRO-C3:C3M.

[0229] The consistent suppression of elastase and collagen synthesis biomarkers following alverestat treatment raises the possibility of impacting on progressive fibrosis, e.g., fibrosis associated with cGVHD BOS or pulmonary fibrosis.

[0230] These data demonstrate the feasibility of treating fibrosis in subjects with inhibitors of neutrophil elastase.

[0231] Example 2: A 12-week study of treating participants with alverestat or placebo (NCT03636347).

[0232] As mentioned above, there is a link between the synthesis of collagen, the main component of the extracellular matrix (ECM), and fibrosis. Indeed, collagen degradation and formation (e.g., by ECM remodeling) are increased in COPD compared to stable disease [Chest 2018;154(4):798-807], and ECM remodeling is a key component of fibrosis [Matrix Biol.(2018)68-69,122-149].

[0233] The aspect of NCT03636347 was to investigate the effect of alberestat on collagen biomarkers in patients with PiZZ, null or rare variant phenotype / genotype alpha-1 antitrypsin deficiency lung disease. The percent change from baseline in several collagen degradation biomarkers was measured in the alberestat and placebo groups over a 12-week period.

[0234] method Inclusion criteria: patients (ages 18-75 years) with confirmed diagnosis of α-1-antitrypsin deficiency and PiZZ, null or other rare gene / phenotype, and serum anti-α-1 antitrypsin level <11 uM; FEV1 ≥20% predicted; computed tomography (CT) scan evidence of emphysema; and non-smokers. Alberestat was administered orally at dose escalation up to 120 mg twice daily, 240 mg twice daily, or 240 mg twice daily. Thus, there were three alberestat treatment groups.

[0235] Collagen degradation biomarkers C1M (type 1 collagen), C6M (type 6 collagen), C4Ma3 (type 4 collagen), and C3M (type 3 collagen) were collected at baseline (i.e., before treatment with alberestat or placebo) and after 12 weeks of treatment with alberestat or placebo.

[0236] Biomarkers related to C3M and C6M were measured by competitive enzyme-linked immunosorbent assay (ELISA) (Nordic Biosciences, Denmark).[1] Biomarkers related to C1M and C4Ma3 were measured using Nordic Bioscience assays [Chest.2017;151(1):47-59; and Lancet Respir Med.2015;3(6):462-472]. C1M, C6M, C4Ma3, and C3M concentrations were measured in ng / mL.

[0237] Samples were taken at baseline (baseline defined as the last value before the first dose of study drug) and after 12 weeks of alverestat or placebo administration (i.e., the value at week 12 or the value at the end of the study).

[0238] Results and Discussion Results are presented as percentage change from baseline for alberestat (three treatment groups represented by one data point) and placebo for each biomarker at 12 weeks following ANCOVA analysis of change from baseline (least squares (LS) means and LS mean differences obtained from models without interactions). SE = standard error. N = number of patients in the study.

[0239] [Table 2]

[0240] From Table 1, patients who received alberestat (alberestat group) had a change from baseline of −0.6% in the collagen degradation biomarker C1M. In contrast, patients who received a placebo (placebo group) had a change from baseline of 17.9% in the collagen degradation biomarker C1M. For C6M, the alberestat group had a change from baseline of 1.1% and the placebo group had a change from baseline of 4.5%. For C4Ma3, the alberestat group had a change from baseline of −6.6% and the placebo group had a change from baseline of 1.9%. For C3M, the alberestat group had a change from baseline of −1.7% and the placebo group had a change from baseline of 4.0%. Overall, the alberestat group had a smaller percent change from baseline in the biomarkers compared to the placebo group.

[0241] conclusion This reveals that all four biomarkers showed a numerically lower turnover (e.g., "lower" and "change" values) with alberestat than with placebo. This confirms a reduction in the turnover rate of ECM and collagen remodeling. ECM remodeling is a key component of fibrosis, and through the attenuation of this process, alberestat can affect fibrosis.

[0242] These data demonstrate the feasibility of treating fibrosis in subjects with inhibitors of neutrophil elastase.

[0243] References [1]Organ et al.Respiratory Research(2019)20:148(https: / / doi.org / 10.1186 / s12931-019-1118-7) [2]Verleden SE, Vos R, Vanaudenaerde BM, Verleden GM, J Thorac Dis 2017;9(8):2650-2659 [3]Geert M.Verleden.The Journal of Heart and Lung Transplantation,Vol 38,No 5,2019,pp493-503 [4] Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, Brozek J, Glanville AR and the ISHLT / ATS / ERS BOS Task Force Committee;Eur Respir J 2014;44:1479-1503 [5]Schlomchik WD, Nature Reviews Immunology, vol.7, pages 340-352(2007). [6]Tiberi S.et al.Eur.Respir.J.2016;47:333-336. [7]Stevens T,Ekholm K,Granse M,Lindahl M,Kozma V,Jungar C,Ottosson T,Falk-Hakansson H,Churg A,Wright JL,Lal H,Sanfridson A.AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase therapeutics.2011;339(1):313-20.Epub 2011 / 07 / 28.doi:10.1124 / jpet.111.182139.PubMed PMID:21791628 [8]Groutas WC,Dou D,Alliston KR,Expert Opin Ther Pat.2011 March;21(3):339-354 [9]Lee SJ,Blood(2017)129(1):30-37

[10] Lee SJ et al;Biol Blood Marrow Transplant 2002;8(8):444-52

[11] Nielsen NJ et al.Am J Transl Res.2013 Apr 19;5(3):303-15

[12] Nedergaard A.et al.J Cachexia Sarcopenia Muscle(2013)4:267-275.

[13] Huang et al. Thorax 2012;67:502-508

[14] Albarbarawi O.et al.Bioanalysis.2013 Aug;5(16):1991-2001(doi:10.4155 / bio.13.164)

[0244] The snowflake is just one of the snowflakes. 1. A method for treating or preventing fibrosis, comprising administering to a human subject in need thereof an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0245] 2. The method of embodiment 1, wherein the fibrosis is selected from the group consisting of arthrofibrosis, liver fibrosis, cardiac fibrosis, mediastinal fibrosis, retroperitoneal fibrosis, bone marrow fibrosis, bridging fibrosis, nephrogenic systemic fibrosis, skin fibrosis, scleroderma, and systemic sclerosis.

[0246] 3. A method for treating or preventing tissue-associated fibrosis, comprising administering to a human subject in need thereof an effective amount of alberestat or a pharma-ceutically acceptable salt and / or solvate thereof.

[0247] 4. The method of embodiment 3, wherein the tissue comprises one or more tissues selected from the group consisting of lung tissue, liver tissue, brain tissue, cardiac tissue, gastrointestinal tissue, and skin tissue.

[0248] 5. The method of embodiment 3 or 4, wherein the tissue is lung tissue.

[0249] 6. The method of any of embodiments 3-5, wherein the tissue is associated with graft-versus-host disease (GVHD).

[0250] 7. A method for treating or preventing disease-associated fibrosis, comprising administering to a human subject in need thereof an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0251] 8. The method of embodiment 7, wherein the disease is one or more selected from the group consisting of graft rejection, graft-versus-host disease (GVHD), chronic pulmonary allograft dysfunction (CLAD), lung transplant-associated bronchiolitis obliterans syndrome (LT-BOS), lung transplant-associated restrictive allograft syndrome (LT-RAS), bronchiolitis obliterans syndrome (BOS), graft-versus-host disease-associated bronchiolitis obliterans syndrome (GVHD BOS), graft-versus-host disease-associated restrictive chronic pulmonary decline (GVHD R-CLFD), liver disease, heart disease, liver cirrhosis, fibrothorax, radiation-induced lung injury, glial scar, arteriosclerosis, kidney disease, Crohn's disease, Dupuytren's contracture, keloid disorders, adhesive capsulitis, rheumatoid arthritis, ulcerative colitis, systemic lupus erythematosus, and hypertension.

[0252] 9. A method for treating or preventing fibrosis associated with graft rejection, comprising administering to a human subject in need thereof an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0253] 10. A method for treating or preventing graft rejection, comprising administering an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof to a human subject in need thereof, wherein said treatment comprises reducing fibrosis in said subject.

[0254] 11. The method of any of embodiments 8 to 10, wherein the graft comprises one or more organs selected from the group consisting of skin, kidney, heart, liver, lung, and pancreas.

[0255] 12. The method of embodiment 11, wherein the graft comprises a lung.

[0256] 13. The method of any of the preceding embodiments, wherein the subject has or is at risk of having lung transplant-associated bronchiolitis obliterans syndrome.

[0257] 14. The method of any of the preceding embodiments, wherein said graft rejection is chronic graft rejection.

[0258] 15. A method for treating or preventing fibrosis associated with lung transplant-associated bronchiolitis obliterans syndrome, comprising administering to a human subject in need thereof an effective amount of alverestat or a pharmacologic acceptable salt and / or solvate thereof.

[0259] 16. A method for treating or preventing lung transplant-associated bronchiolitis obliterans syndrome, comprising administering an effective amount of alvelestat or a pharmacologic acceptable salt and / or solvate thereof to a human subject in need thereof, wherein said treatment comprises reducing fibrosis in said subject.

[0260] 17. A method for treating or preventing fibrosis associated with graft-versus-host disease (GVHD), comprising administering to a human subject in need thereof an effective amount of alverestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0261] 18. A method for treating or preventing graft-versus-host disease (GVHD), comprising administering an effective amount of alverestat or a pharma- ceutically acceptable salt and / or solvate thereof to a human subject in need thereof, wherein said treatment comprises reducing fibrosis in said subject.

[0262] 19. The method of any of embodiments 8 or 17-18, wherein the GVHD is chronic GVHD (cGVHD).

[0263] 20. The method of embodiment 19, wherein the GVHD is acute GVHD (aGVHD).

[0264] 21. The method of any of embodiments 8 or 17-20, wherein the GVHD appears after bone marrow transplantation.

[0265] 22. The method of any one of embodiments 8 or 17 to 21, wherein the GVHD appears after hematopoietic stem cell transplantation.

[0266] 23. The method of any one of embodiments 8 or 17-22, wherein the GVHD is characterized by damage to one or more selected from the group consisting of eyes, joints, fascia, genitals, lungs, liver, skin, or digestive tract (e.g., mouth, esophagus).

[0267] 24. The method of any one of embodiments 8 or 17-23, wherein the GVHD is characterized by damage to one or more selected from the group consisting of the lungs, liver, skin, or gastrointestinal tract.

[0268] 25. The method of any one of embodiments 8 or 17-24, wherein the subject has moderate or severe cGVHD.

[0269] 26. The method of any one of embodiments 8 or 17-25, wherein the subject has or is at risk of having bronchiolitis obliterans syndrome.

[0270] 27. A method for treating or preventing fibrosis associated with bronchiolitis obliterans syndrome (BOS) and GVHD, comprising administering to a human subject in need thereof an effective amount of alverestat or a pharma- ceutically acceptable salt and / or solvate thereof.

[0271] 28. A method for treating or preventing bronchiolitis obliterans syndrome (BOS) associated with GVHD, comprising administering an effective amount of alverestat or a pharma- ceutically acceptable salt and / or solvate thereof to a human subject in need thereof, wherein said treatment comprises reducing fibrosis in said subject.

[0272] 29. The method of any of embodiments 8 or 27-28, wherein the BOS is associated with hematopoietic stem cell transplantation.

[0273] 30. The method of embodiment 29, wherein said hematopoietic stem cell transplantation is an allogeneic hematopoietic cell transplantation.

[0274] 31. The method of any of embodiments 8 or 27-28, wherein the BOS is associated with bone marrow transplantation.

[0275] 32. The method of any of the preceding embodiments, wherein the subject has neutrophilia.

[0276] 33. The method of embodiment 32, wherein said neutrophilia is airway neutrophilia.

[0277] 34. The method of any of the preceding embodiments, wherein alverestat or a pharma- ceutically acceptable salt and / or solvate thereof is administered to the subject prior to transplantation.

[0278] 35. The method according to any one of embodiments 1 to 33, wherein alberestat or a pharma- ceutically acceptable salt and / or solvate thereof is administered to the subject after transplantation.

[0279] 36. The method of any of the preceding embodiments, wherein said treating or preventing comprises inhibiting neutrophil elastase.

[0280] 37. The method of any of the preceding embodiments, wherein said treating, preventing, or reducing fibrosis comprises reducing the level of one or more biomarkers.

[0281] 38. The method of any of the preceding embodiments, wherein the subject has elevated levels of one or more biomarkers.

[0282] 39. The method of any of the preceding embodiments, wherein said treating, preventing, or reducing fibrosis comprises reducing the level of one or more biomarkers for 12 weeks.

[0283] 40. The method of any of embodiments 37-39, wherein the biomarker is a collagen biomarker.

[0284] 41. The method of embodiment 40, wherein the collagen biomarker is a collagen type III biomarker and / or a collagen type IV biomarker.

[0285] 42. The method of embodiment 40 or 41, wherein the collagen biomarker is the N-terminal propeptide of collagen type III (PRO-C3) and / or the N-terminal propeptide of collagen type VI (PRO-C6).

[0286] 43. The method of embodiment 40 or 41, wherein the collagen biomarker is the N-terminal propeptide of type III collagen (PRO-C3).

[0287] 44. The method of any of embodiments 37-39, wherein the biomarker is an elastin biomarker.

[0288] 45. The method of embodiment 44, wherein the elastin biomarker is selected from desmosine (DES) and isodesmosine (IDES).

[0289] 46. ​​The method of any of the previous embodiments, wherein said treating or preventing comprises improving or preventing a decline in FEV1% predicted in said subject.

[0290] 47. The method of any of the preceding embodiments, wherein said treating or preventing comprises improving or preventing a decrease in the subject's BOS grade.

[0291] 48. The method of any of the preceding embodiments, wherein the treating of cGVHD comprises improving a cGVHD severity score in the subject.

[0292] 49. The method of any of the preceding embodiments, wherein said treating cGVHD comprises improving the Lee cGVHD Symptom Scale in a subject, particularly the Lee cGVHD Symptom Scale pulmonary score in a subject suffering from cGVHD affecting the lungs.

[0293] 50. The method of any of the preceding embodiments, comprising improving pulmonary function in a subject.

[0294] 51. The method of any of the preceding embodiments, comprising preventing deterioration of pulmonary function in the subject.

[0295] 52. The method of any of the preceding embodiments, comprising preventing progression or worsening of the disease in a subject.

[0296] 53. The method of any of the preceding embodiments, wherein alberestat is in the form of a free base.

[0297] 54. The method of any of the preceding embodiments, wherein the alberestat is in the form of alberestat tosylate.

[0298] 55. The method of any of the preceding embodiments, comprising administering alberestat, or a pharma- ceutically acceptable salt and / or solvate thereof, twice daily.

[0299] 56. The method of any of the preceding embodiments, comprising administering arvelestat or a pharma- ceutically acceptable salt and / or solvate thereof at a dose of up to 240 mg of arvelestat twice daily.

[0300] 57. The method of any of the preceding embodiments, comprising administering alberestat or a pharma- ceutically acceptable salt and / or solvate thereof at a dose of 60 mg, 120 mg, 180 mg, or 240 mg of alberestat twice daily.

[0301] 58. The method of any of the preceding embodiments, comprising administering alberestat or a pharma- ceutically acceptable salt and / or solvate thereof at a dose of 240 mg of alberestat twice daily.

[0302] 59. The method of any of the preceding embodiments, comprising administering alberestat or a pharma- ceutically acceptable salt and / or solvate thereof at a dose of 60 mg twice daily for a first period of time, followed by 120 mg twice daily for a second period of time, followed by 180 mg twice daily for a third period of time, thereafter 240 mg twice daily.

[0303] 60. The method of any of the preceding embodiments comprising administering arvelestat or a pharma- ceutically acceptable salt and / or solvate thereof at a dose of 60 mg twice daily for 2 weeks, followed by 120 mg twice daily for 2 weeks, followed by 180 mg twice daily for 2 weeks, then 240 mg twice daily.

[0304] 61. The method of any of the preceding embodiments, comprising administering alberestat or a pharma- ceutically acceptable salt and / or solvate thereof by oral administration.

[0305] 62. The method of any of the preceding embodiments, further comprising administering to the subject one or more immunosuppressive agents.

[0306] 63. A method for identifying a human subject in need of treatment with alverestat or a pharma- ceutically acceptable salt thereof, comprising determining the levels of desmosine and isodesmosine in a sample from the subject, wherein elevated levels of desmosine and isodesmosine compared to baseline identify the subject in need of the treatment.

[0307] 64. The method of embodiment 63, wherein said elevated levels of desmosine and isodesmosine compared to baseline are equivalent to elevated neutrophil elastase activity.

[0308] 65. A method for determining neutrophil elastase activity, comprising assessing levels of desmosine and isodesmosine in a sample from a human subject, wherein elevated levels of desmosine and isodesmosine compared to baseline indicate elevated neutrophil elastase activity.

[0309] 66. The method of any of embodiments 63-65, wherein the subject has been diagnosed with GVHD.

[0310] 67. The method of embodiment 66, wherein the GVHD is GVHD BOS.

[0311] 68. The method of embodiment 66 or 67, wherein the subject has undergone a hematopoietic stem cell transplant.

[0312] 69. A method according to any of embodiments 63 to 68, wherein the levels of said biomarkers, such as desmosine and isodesmosine, are measured by chromatography and / or mass spectrometry, for example isotope dilution liquid chromatography tandem with mass spectrometry.

[0313] 70. The method of any of embodiments 63 to 69, wherein the sample from the subject is a blood sample, e.g. a plasma sample.

Claims

1. 1. A method for treating or preventing fibrosis, comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a human subject in need thereof.

2. 2. The method of claim 1, wherein the fibrosis is selected from the group consisting of liver fibrosis, arthrofibrosis, cardiac fibrosis, mediastinal fibrosis, retroperitoneal fibrosis, bone marrow fibrosis, bridging fibrosis, liver fibrosis, nephrogenic systemic fibrosis, skin fibrosis, scleroderma, and systemic sclerosis, e.g., liver fibrosis.

3. 1. A method for treating or preventing tissue-associated fibrosis, comprising administering to a human subject in need thereof an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof.

4. 4. The method of claim 3, wherein the tissue comprises one or more tissues selected from the group consisting of liver tissue, lung tissue, brain tissue, cardiac tissue, gastrointestinal tissue, and skin tissue, e.g., the tissue is lung tissue.

5. The method of claim 3 or 4, wherein the tissue is associated with graft-versus-host disease (GVHD).

6. 1. A method for treating or preventing disease-associated fibrosis, comprising administering to a human subject in need thereof an effective amount of alberestat or a pharma- ceutically acceptable salt and / or solvate thereof.

7. The diseases include graft rejection, graft-versus-host disease (GVHD), chronic pulmonary allograft dysfunction (CLAD), lung transplant-associated bronchiolitis obliterans syndrome (LT-BOS), lung transplant-associated restrictive allograft syndrome (LT-RAS), bronchiolitis obliterans syndrome (BOS), graft-versus-host disease-associated bronchiolitis obliterans syndrome (GVHD BOS), graft-versus-host disease-associated restrictive chronic pulmonary decline (GVHD 7. The method of claim 6, wherein the disease is one or more selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatosis, non-alcoholic steatohepatitis (NASH), and cirrhosis, for example, the disease is one or more selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatosis, non-alcoholic steatohepatitis (NASH), and cirrhosis.

8. A method for treating or preventing fibrosis associated with graft rejection, comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a human subject in need thereof.

9. A method for treating or preventing graft rejection, comprising administering an effective amount of alvelestat or a pharma- ceutically acceptable salt and / or solvate thereof to a human subject in need thereof, wherein said treatment comprises reducing fibrosis in said subject.

10. The method according to any one of claims 7 to 9, wherein the graft comprises one or more organs selected from the group consisting of skin, kidney, heart, liver, lung, and pancreas, for example, the graft comprises a lung.

11. (i) the subject has or is at risk of having lung transplant-associated bronchiolitis obliterans syndrome, and / or (ii) the graft rejection is chronic graft rejection; A method according to any preceding claim.

12. A method for treating or preventing fibrosis associated with lung transplant-associated bronchiolitis obliterans syndrome, comprising administering an effective amount of alvelestat or a pharmacologic acceptable salt and / or solvate thereof to a human subject in need thereof.

13. A method for treating or preventing lung transplant-associated bronchiolitis obliterans syndrome, comprising administering an effective amount of alvelestat or a pharmacologic acceptable salt and / or solvate thereof to a human subject in need thereof, wherein the treatment comprises reducing fibrosis in the subject.

14. 1. A method for treating or preventing fibrosis associated with graft-versus-host disease (GVHD), comprising administering an effective amount of alverestat or a pharma- ceutically acceptable salt and / or solvate thereof to a human subject in need thereof.

15. A method for treating or preventing graft-versus-host disease (GVHD), comprising administering an effective amount of alverestat or a pharma- ceutically acceptable salt and / or solvate thereof to a human subject in need thereof, wherein the treatment comprises reducing fibrosis in the subject.

16. (i) the GVHD is chronic GVHD (cGVHD) or the GVHD is acute GVHD (aGVHD); and / or (ii) the GVHD occurs after bone marrow transplantation; and / or (iii) the GVHD occurs after hematopoietic stem cell transplantation; and / or (iv) the GVHD is characterized by damage to one or more selected from the group consisting of eyes, joints, fascia, genitals, lungs, liver, skin, or gastrointestinal tract (e.g., mouth, esophagus); and / or (v) the GVHD is characterized by damage to one or more selected from the group consisting of the lungs, liver, skin, or gastrointestinal tract; and / or (vi) the subject has moderate or severe cGVHD, and / or (vii) the subject has or is at risk of having bronchiolitis obliterans syndrome; The method according to any one of claims 7 or 14-15.

17. A method for treating or preventing fibrosis associated with bronchiolitis obliterans syndrome (BOS) and GVHD, comprising administering an effective amount of alvelestat or a pharmacologic acceptable salt and / or solvate thereof to a human subject in need thereof.

18. A method for treating or preventing bronchiolitis obliterans syndrome (BOS) associated with GVHD, comprising administering an effective amount of alvelestat or a pharma- ceutical acceptable salt and / or solvate thereof to a human subject in need thereof, wherein the treatment comprises reducing fibrosis in the subject.

19. (i) the BOS is associated with hematopoietic stem cell transplantation, e.g., the hematopoietic stem cell transplantation is an allogeneic hematopoietic cell transplantation; or (ii) the BOS is associated with bone marrow transplantation; The method according to any one of claims 7 or 17 to 18.

20. (i) the subject has neutrophilia, e.g., the neutrophilia is airway neutrophilia; and / or (ii) alberestat or a pharma- ceutically acceptable salt and / or solvate thereof is administered to the subject before or after transplantation; and / or (iii) the treating or preventing comprises inhibiting neutrophil elastase; A method according to any preceding claim.

21. (i) the treating, preventing, or reducing fibrosis comprises reducing the level of one or more biomarkers; and / or (ii) the subject has elevated levels of one or more biomarkers; and / or (iii) the treating, preventing, or reducing fibrosis comprises reducing the level of one or more biomarkers for 12 weeks; A method according to any preceding claim.

22. (i) the biomarker is a collagen biomarker; For example, the collagen biomarker is a type III collagen biomarker and / or a type IV collagen biomarker, and optionally The collagen biomarker is the N-terminal propeptide of type III collagen (PRO-C3) and / or the N-terminal propeptide of type VI collagen (PRO-C6), for example: the collagen biomarker is the N-terminal propeptide of type III collagen (PRO-C3); or (ii) the biomarker is an elastin biomarker; For example, the elastin biomarker is selected from desmosine (DES) and isodesmosine (IDES).

22. The method of claim 21.

23. (i) the treatment or prevention comprises improving or preventing a decline in FEV1% predicted in the subject; and / or (ii) the treatment or prevention comprises improving or preventing a decrease in the BOS grade in the subject; and / or (iii) treating the cGVHD comprises improving a cGVHD severity score in the subject; and / or (iv) the treatment of cGVHD comprises improving the subject's Lee cGVHD Symptom Scale, particularly the Lee cGVHD Symptom Scale pulmonary score in subjects with cGVHD affecting the lungs; A method according to any preceding claim.

24. (i) improving pulmonary function in a subject; and / or (ii) preventing a deterioration of pulmonary function in a subject; and / or (iii) preventing progression or worsening of the disease in a subject; A method according to any preceding claim.

25. (i) arvelestat is in the form of the free base; and / or (ii) alberestat is in the form of alberestat tosylate; A method according to any preceding claim.

26. (i) administering alberestat or a pharma- ceutically acceptable salt and / or solvate thereof twice daily; and / or (ii) administering alberestat or a pharma- ceutically acceptable salt and / or solvate thereof at a dose of up to 240 mg of alberestat twice daily; and / or (iii) administering arvelestat or a pharma- ceutically acceptable salt and / or solvate thereof twice daily at a dose of 60 mg, 120 mg, 180 mg, or 240 mg of arvelestat; and / or (iv) administering alberestat or a pharma- ceutically acceptable salt and / or solvate thereof at a dose of 240 mg of alberestat twice daily; and / or (v) administering alberestat or a pharma- ceutically acceptable salt and / or solvate thereof at a dose of 60 mg twice daily for a first period, followed by 120 mg twice daily for a second period, followed by 180 mg twice daily for a third period, thereafter 240 mg twice daily; and / or (vi) administering arvelestat or a pharma- ceutically acceptable salt and / or solvate thereof at a dose of 60 mg twice daily for 2 weeks, followed by 120 mg twice daily for 2 weeks, followed by 180 mg twice daily for 2 weeks, then 240 mg twice daily; and / or (vii) administering alberestat or a pharma- ceutically acceptable salt and / or solvate thereof by oral administration; and / or (viii) further comprising administering to the subject one or more immunosuppressive agents. A method according to any preceding claim.

27. 1. A method for identifying a human subject in need of treatment with alverestat or a pharma- ceutically acceptable salt thereof, comprising determining the levels of desmosine and isodesmosine in a sample from the subject, wherein elevated levels of desmosine and isodesmosine compared to baseline identify the subject in need of the treatment.

28. 28. The method of claim 27, wherein the elevated levels of desmosine and isodesmosine compared to baseline equates to elevated neutrophil elastase activity.

29. 1. A method for determining neutrophil elastase activity, comprising assessing levels of desmosine and isodesmosine in a sample from a human subject, wherein elevated levels of desmosine and isodesmosine compared to baseline indicate elevated neutrophil elastase activity.

30. (i) the subject has been diagnosed with GVHD, and optionally the GVHD is GVHD BOS, and / or the subject has undergone a hematopoietic stem cell transplant, and / or (ii) the levels of said biomarkers, such as desmosine and isodesmosine, are measured by chromatography and / or mass spectrometry, for example isotope dilution liquid chromatography tandem with mass spectrometry; and / or (vi) the sample from the subject is a blood sample, e.g., a plasma sample; 30. The method according to any one of claims 27 to 29.